{
  "meta": {
    "version": "1.0.0",
    "totalQuestions": 329,
    "lastUpdated": "2026-03-01",
    "author": "MedPhys Speed Quiz",
    "notes": "Each question needs: id (unique), q (question text), a (correct answer ‚Äî MUST exactly match one choice), c (4 choices), s (section id), e (explanation shown after answering wrong). To add questions: just append to the section array. To add a section: add to 'sections' and create matching array in 'questions'."
  },
  "sections": [
    {
      "id": "srt",
      "name": "SRT & Small Fields",
      "icon": "üéØ",
      "color": "#f472b6",
      "description": "Stereotactic, TRS-483, Winston-Lutz"
    },
    {
      "id": "qa",
      "name": "QA & Tolerances",
      "icon": "üìã",
      "color": "#60a5fa",
      "description": "TG-142, gamma, daily checks"
    },
    {
      "id": "equip",
      "name": "Equipment",
      "icon": "‚öôÔ∏è",
      "color": "#fbbf24",
      "description": "Varian, Elekta, MLC, dose rates"
    },
    {
      "id": "eclipse",
      "name": "Eclipse & TPS",
      "icon": "üíª",
      "color": "#c084fc",
      "description": "AAA, AcurosXB, beam models"
    },
    {
      "id": "dosimetry",
      "name": "Dosimetry",
      "icon": "‚ò¢Ô∏è",
      "color": "#fb923c",
      "description": "TRS-398, calibration, corrections"
    },
    {
      "id": "nucmed",
      "name": "Nuclear Medicine",
      "icon": "‚öõÔ∏è",
      "color": "#2dd4bf",
      "description": "Gamma cameras, PET, radiopharmaceuticals"
    },
    {
      "id": "diag",
      "name": "Diagnostic Radiology",
      "icon": "ü©ª",
      "color": "#38bdf8",
      "description": "X-ray, CT, mammography, dose metrics"
    },
    {
      "id": "radiobio",
      "name": "Radiobiology",
      "icon": "üß¨",
      "color": "#a3e635",
      "description": "LQ model, fractionation, OER, RBE"
    },
    {
      "id": "radprot",
      "name": "Radiation Protection",
      "icon": "üõ°Ô∏è",
      "color": "#f97316",
      "description": "Shielding, dose limits, ALARA"
    },
    {
      "id": "regs",
      "name": "SA Regulatory",
      "icon": "üèõÔ∏è",
      "color": "#34d399",
      "description": "SAHPRA, HPCSA, SASQART"
    }
  ],
  "questions": {
    "srt": [
      {
        "id": "srt01",
        "q": "SRS Winston-Lutz tolerance?",
        "a": "‚â§ 1 mm",
        "c": [
          "‚â§ 0.5 mm",
          "‚â§ 1 mm",
          "‚â§ 2 mm",
          "‚â§ 3 mm"
        ],
        "e": "SRS demands sub-mm precision. Winston-Lutz verifies radiation and mechanical isocentre coincidence."
      },
      {
        "id": "srt02",
        "q": "Small-field dosimetry protocol?",
        "a": "TRS-483",
        "c": [
          "TG-51",
          "TRS-398",
          "TRS-483",
          "TG-106"
        ],
        "e": "IAEA TRS-483 provides the framework for reference and relative dosimetry of small and non-standard fields."
      },
      {
        "id": "srt03",
        "q": "SBRT motion management threshold?",
        "a": "> 5 mm",
        "c": [
          "> 2 mm",
          "> 5 mm",
          "> 10 mm",
          "> 15 mm"
        ],
        "e": "If tumour motion exceeds 5 mm on 4D-CT, active management (gating, DIBH, compression) is required."
      },
      {
        "id": "srt04",
        "q": "FFF beam profile shape?",
        "a": "Peaked (non-flat)",
        "c": [
          "Flat",
          "Peaked (non-flat)",
          "Concave",
          "Saddle-shaped"
        ],
        "e": "Without the flattening filter the beam has a peaked forward intensity, sharper penumbra, and lower out-of-field dose."
      },
      {
        "id": "srt05",
        "q": "SRS planning grid size?",
        "a": "‚â§ 2 mm",
        "c": [
          "‚â§ 1 mm",
          "‚â§ 2 mm",
          "‚â§ 2.5 mm",
          "‚â§ 5 mm"
        ],
        "e": "Small targets require fine calculation grids. 1 mm ideal for SRS; 2 mm acceptable for SBRT."
      },
      {
        "id": "srt06",
        "q": "Ideal conformity index?",
        "a": "1.0",
        "c": [
          "0",
          "0.5",
          "1.0",
          "2.0"
        ],
        "e": "CI = prescription isodose volume / target volume. A value of 1.0 means perfect conformity."
      },
      {
        "id": "srt07",
        "q": "SBRT fractionation (SASQART)?",
        "a": "‚â• 5 Gy, ‚â§ 5 fx",
        "c": [
          "‚â• 2 Gy, ‚â§ 30 fx",
          "‚â• 5 Gy, ‚â§ 5 fx",
          "‚â• 8 Gy, ‚â§ 3 fx",
          "‚â• 10 Gy, 1 fx"
        ],
        "e": "SASQART 2025 defines SBRT as ‚â• 5 Gy per fraction in ‚â§ 5 fractions. SRS is single-fraction intracranial."
      },
      {
        "id": "srt08",
        "q": "E2E test is?",
        "a": "CT ‚Üí plan ‚Üí deliver ‚Üí measure",
        "c": [
          "Output check",
          "CT ‚Üí plan ‚Üí deliver ‚Üí measure",
          "MLC calibration",
          "Beam scan"
        ],
        "e": "End-to-end tests the full clinical chain using an anthropomorphic phantom. Gold standard for SRT commissioning."
      },
      {
        "id": "srt09",
        "q": "Gradient index measures?",
        "a": "Dose falloff steepness",
        "c": [
          "Target coverage",
          "Dose falloff steepness",
          "OAR sparing",
          "Output constancy"
        ],
        "e": "GI = V50%/Vprescription. Lower GI = steeper dose falloff = better sparing of surrounding tissue."
      },
      {
        "id": "srt10",
        "q": "TG-101 covers?",
        "a": "SBRT/SRS guidance",
        "c": [
          "Linac QA",
          "IMRT commissioning",
          "SBRT/SRS guidance",
          "Shielding"
        ],
        "e": "AAPM TG-101 provides comprehensive guidance for SBRT including tolerances, QA, and clinical protocols."
      },
      {
        "id": "srt11",
        "q": "TRS-483 small-field condition #1?",
        "a": "Loss of lateral CPE",
        "c": [
          "Loss of lateral CPE",
          "Detector saturation",
          "Beam hardening",
          "Penumbra widening"
        ],
        "e": "When field size < lateral electron range, charged particle equilibrium is lost, invalidating standard dosimetry."
      },
      {
        "id": "srt12",
        "q": "Recommended SRS detector?",
        "a": "microDiamond",
        "c": [
          "Farmer chamber",
          "microDiamond",
          "Parallel plate",
          "Pencil chamber"
        ],
        "e": "PTW 60019 microDiamond has ~0.004 mm¬≥ sensitive volume ‚Äî ideal for small-field output factors per TRS-483."
      },
      {
        "id": "srt13",
        "q": "Paddick CI penalises?",
        "a": "Over- and under-coverage",
        "c": [
          "Only underdose",
          "Only overdose",
          "Over- and under-coverage",
          "Conformity only"
        ],
        "e": "PCI = (TV_PIV)¬≤/(TV √ó PIV). Unlike simple CI, it penalises both target miss and excessive irradiation."
      },
      {
        "id": "srt14",
        "q": "Frame-based vs frameless SRS?",
        "a": "Frameless is current standard",
        "c": [
          "Frame-based is standard",
          "Frameless is current standard",
          "No difference",
          "Frameless is experimental"
        ],
        "e": "Frameless SRS with thermoplastic masks + IGRT is now standard. SASQART: sole laser positioning no longer acceptable."
      },
      {
        "id": "srt15",
        "q": "SBRT isocenter tolerance?",
        "a": "‚â§ 2 mm",
        "c": [
          "‚â§ 0.5 mm",
          "‚â§ 1 mm",
          "‚â§ 2 mm",
          "‚â§ 5 mm"
        ],
        "e": "SBRT allows slightly larger tolerance than SRS (‚â§ 1 mm) due to larger PTV margins, but still tight."
      },
      {
        "id": "srt16",
        "q": "CyberKnife tracking method?",
        "a": "Real-time kV image guidance",
        "c": [
          "Cone-beam CT repositioning",
          "Real-time kV image guidance",
          "Optical surface monitoring",
          "Respiratory gating only"
        ],
        "e": "CyberKnife uses orthogonal kV imaging to track fiducials or bony anatomy in real-time, correcting the robotic arm during delivery.",
        "d": 5
      },
      {
        "id": "srt17",
        "q": "Gamma Knife source isotope?",
        "a": "Co-60",
        "c": [
          "Cs-137",
          "Co-60",
          "Ir-192",
          "I-125"
        ],
        "e": "Leksell Gamma Knife uses ~192 Co-60 sources arranged in a hemisphere to converge on a stereotactic target.",
        "d": 3
      },
      {
        "id": "srt18",
        "q": "SBRT lung typical dose?",
        "a": "54 Gy in 3 fractions",
        "c": [
          "60 Gy in 30 fx",
          "54 Gy in 3 fractions",
          "70 Gy in 35 fx",
          "20 Gy in 5 fx"
        ],
        "e": "RTOG 0236 established 54 Gy/3 fx for peripheral T1-T2 NSCLC. Central lesions require more conservative fractionation.",
        "d": 5
      },
      {
        "id": "srt19",
        "q": "ITV accounts for?",
        "a": "Respiratory tumour motion",
        "c": [
          "Setup uncertainty",
          "Respiratory tumour motion",
          "Organ deformation",
          "Machine isocentre error"
        ],
        "e": "Internal Target Volume encompasses all CTV positions across the breathing cycle, typically defined from 4D-CT.",
        "d": 4
      },
      {
        "id": "srt20",
        "q": "DIBH stands for?",
        "a": "Deep Inspiration Breath Hold",
        "c": [
          "Digital Image Beam Holding",
          "Deep Inspiration Breath Hold",
          "Dose Intensity Beam Hardening",
          "Dynamic Intensity Beam Hold"
        ],
        "e": "Patient holds breath at deep inspiration to immobilise the tumour and move heart away from the treatment field (e.g., left breast).",
        "d": 3
      },
      {
        "id": "srt21",
        "q": "V12Gy constraint in brain SRS?",
        "a": "Radionecrosis risk predictor",
        "c": [
          "Target coverage metric",
          "Radionecrosis risk predictor",
          "OAR maximum dose",
          "Conformity index variant"
        ],
        "e": "Volume receiving ‚â•12 Gy correlates with symptomatic radionecrosis risk. V12 < 10 cm¬≥ is generally considered safe.",
        "d": 6
      },
      {
        "id": "srt22",
        "q": "ExacTrac uses?",
        "a": "IR + stereoscopic kV X-rays",
        "c": [
          "CBCT volumetric imaging",
          "IR + stereoscopic kV X-rays",
          "MR-guided positioning",
          "Ultrasound-guided setup"
        ],
        "e": "Brainlab ExacTrac combines infrared surface tracking with stereoscopic kV X-ray imaging for 6DOF correction.",
        "d": 5
      },
      {
        "id": "srt23",
        "q": "TRS-483 field output correction factor?",
        "a": "k_Qclin,Qmsr",
        "c": [
          "k_Q",
          "k_s",
          "k_Qclin,Qmsr",
          "k_TP"
        ],
        "e": "The detector-specific output correction factor converts readings in small clinical fields relative to the machine-specific reference field.",
        "d": 7
      },
      {
        "id": "srt24",
        "q": "SBRT spine typical constraint?",
        "a": "Cord Dmax < 14 Gy (1 fx)",
        "c": [
          "Cord mean dose < 5 Gy",
          "Cord Dmax < 14 Gy (1 fx)",
          "Cord V20Gy < 10% volume",
          "Cord Dmax < 30 Gy total"
        ],
        "e": "Single-fraction spine SBRT limits cord point max to ~14 Gy (0.03cc). Multi-fraction limits are proportionally higher.",
        "d": 7
      },
      {
        "id": "srt25",
        "q": "CALC: GI = V50%/V100%. If V50% = 30 cm¬≥ and V100% = 10 cm¬≥, GI = ?",
        "a": "3.0",
        "c": [
          "0.33",
          "2.0",
          "3.0",
          "5.0"
        ],
        "e": "Gradient Index = 30/10 = 3.0. Lower is better ‚Äî indicates steeper dose falloff around the target.",
        "d": 5
      },
      {
        "id": "srt26",
        "q": "Adaptive radiotherapy advantage in SBRT?",
        "a": "Accounts for inter-fraction anatomy changes",
        "c": [
          "Faster delivery times",
          "Accounts for inter-fraction anatomy changes",
          "Reduces treatment cost",
          "Eliminates need for immobilisation"
        ],
        "e": "Adaptive RT re-optimises plans based on daily anatomy (e.g., Ethos, MR-Linac), critical for abdominal SBRT where organs shift.",
        "d": 5
      },
      {
        "id": "srt27",
        "q": "MR-Linac advantage for SBRT?",
        "a": "Real-time soft tissue visualisation",
        "c": [
          "Higher dose rate than conventional",
          "Real-time soft tissue visualisation",
          "No need for treatment planning",
          "Eliminates respiratory motion"
        ],
        "e": "MR-Linac (e.g., Elekta Unity, ViewRay) provides continuous MR imaging during delivery ‚Äî superior soft tissue contrast without ionising radiation.",
        "d": 5
      },
      {
        "id": "srt28",
        "q": "Prescription isodose for SRS (typical)?",
        "a": "50-80%",
        "c": [
          "95-100%",
          "80-90%",
          "50-80%",
          "30-50%"
        ],
        "e": "SRS often prescribes to a lower isodose line (50-80%) to achieve steep dose gradients and hot spots within the target.",
        "d": 5
      },
      {
        "id": "srt29",
        "q": "CALC: Paddick CI = (TV_PIV)¬≤/(TV √ó PIV). TV=5cc, PIV=6cc, TV_PIV=4.5cc. PCI=?",
        "a": "0.675",
        "c": [
          "0.45",
          "0.675",
          "0.75",
          "0.90"
        ],
        "e": "PCI = (4.5)¬≤ / (5 √ó 6) = 20.25 / 30 = 0.675. Values closer to 1.0 indicate better conformity.",
        "d": 7
      },
      {
        "id": "srt30",
        "q": "Oligometastatic disease SBRT rationale?",
        "a": "Ablate limited mets, delay systemic Rx",
        "c": [
          "Replace chemotherapy entirely",
          "Ablate limited mets, delay systemic Rx",
          "Cure all stage IV cancers",
          "Reduce follow-up imaging need"
        ],
        "e": "SBRT to 1-5 oligomets can achieve durable local control, potentially deferring or eliminating the need for systemic therapy.",
        "d": 4
      }
    ],
    "qa": [
      {
        "id": "qa01",
        "q": "Daily output tolerance?",
        "a": "¬± 3%",
        "c": [
          "¬± 1%",
          "¬± 2%",
          "¬± 3%",
          "¬± 5%"
        ],
        "e": "TG-142 daily output check. Exceeding this requires investigation before treating patients."
      },
      {
        "id": "qa02",
        "q": "Monthly output tolerance?",
        "a": "¬± 2%",
        "c": [
          "¬± 1%",
          "¬± 2%",
          "¬± 3%",
          "¬± 5%"
        ],
        "e": "Monthly checks use a calibrated chamber. Tighter than daily because measurement is more rigorous."
      },
      {
        "id": "qa03",
        "q": "Annual calibration accuracy?",
        "a": "¬± 1%",
        "c": [
          "¬± 0.5%",
          "¬± 1%",
          "¬± 2%",
          "¬± 3%"
        ],
        "e": "TRS-398 absolute calibration target. The gold-standard reference that monthly and daily checks anchor to."
      },
      {
        "id": "qa04",
        "q": "Linac QA TG?",
        "a": "TG-142",
        "c": [
          "TG-51",
          "TG-142",
          "TG-119",
          "TG-106"
        ],
        "e": "TG-142 replaced TG-40, covering daily/monthly/annual QA tolerances for modern linacs."
      },
      {
        "id": "qa05",
        "q": "IMRT commissioning TG?",
        "a": "TG-119",
        "c": [
          "TG-142",
          "TG-119",
          "TG-101",
          "TG-218"
        ],
        "e": "TG-119 provides benchmark plans and confidence limits for IMRT commissioning verification."
      },
      {
        "id": "qa06",
        "q": "Beam data commissioning TG?",
        "a": "TG-106",
        "c": [
          "TG-142",
          "TG-119",
          "TG-106",
          "TG-51"
        ],
        "e": "TG-106 covers beam data commissioning: scanning systems, detectors, measurement protocols."
      },
      {
        "id": "qa07",
        "q": "Standard IMRT gamma criteria?",
        "a": "3%/3mm ‚â• 95%",
        "c": [
          "1%/1mm ‚â• 99%",
          "2%/2mm ‚â• 97%",
          "3%/3mm ‚â• 95%",
          "5%/5mm ‚â• 90%"
        ],
        "e": "TG-218 recommends 3%/3mm with ‚â• 95% pass as universal tolerance and 90% as action limit."
      },
      {
        "id": "qa08",
        "q": "Picket fence checks?",
        "a": "MLC leaf positioning",
        "c": [
          "Output",
          "MLC leaf positioning",
          "Gantry angle",
          "kV quality"
        ],
        "e": "Equally-spaced MLC strips on EPID/film reveal systematic leaf position errors."
      },
      {
        "id": "qa09",
        "q": "DLG stands for?",
        "a": "Dosimetric Leaf Gap",
        "c": [
          "Dynamic Leaf Gate",
          "Dosimetric Leaf Gap",
          "Dose Limiting Grid",
          "Digital Leaf Gauge"
        ],
        "e": "Accounts for radiation leaking through rounded MLC leaf ends. Measured via sweeping gap technique."
      },
      {
        "id": "qa10",
        "q": "TG-218 covers?",
        "a": "IMRT verification QA",
        "c": [
          "Commissioning",
          "IMRT verification QA",
          "Electron dosimetry",
          "Brachytherapy"
        ],
        "e": "Tolerances and methodology for patient-specific IMRT/VMAT measurement-based verification."
      },
      {
        "id": "qa11",
        "q": "Imaging-treatment isocenter (SRS)?",
        "a": "‚â§ 1 mm",
        "c": [
          "‚â§ 0.5 mm",
          "‚â§ 1 mm",
          "‚â§ 2 mm",
          "‚â§ 3 mm"
        ],
        "e": "kV CBCT isocenter must coincide with treatment isocenter within 1 mm for SRS."
      },
      {
        "id": "qa12",
        "q": "Monthly MLC position tolerance?",
        "a": "¬± 1 mm",
        "c": [
          "¬± 0.5 mm",
          "¬± 1 mm",
          "¬± 2 mm",
          "¬± 3 mm"
        ],
        "e": "Each leaf must position within 1 mm of planned. Checked with picket fence and log file analysis."
      },
      {
        "id": "qa13",
        "q": "TG-275 covers?",
        "a": "Physics plan review",
        "c": [
          "Linac QA",
          "Physics plan review",
          "SBRT",
          "Shielding"
        ],
        "e": "Strategies for effective physics review of treatment plans ‚Äî catching errors before delivery."
      },
      {
        "id": "qa14",
        "q": "Varian MPC checks?",
        "a": "Output, geometry, symmetry",
        "c": [
          "MLC positioning only",
          "Output, geometry, symmetry",
          "Imaging quality only",
          "Couch accuracy only"
        ],
        "e": "Machine Performance Check: automated daily QA verifying output, beam characteristics, and geometry."
      },
      {
        "id": "qa15",
        "q": "Daily laser tolerance (SRS)?",
        "a": "¬± 1 mm",
        "c": [
          "¬± 0.5 mm",
          "¬± 1 mm",
          "¬± 2 mm",
          "¬± 3 mm"
        ],
        "e": "SRS/SBRT laser alignment is tighter than conventional (¬± 2 mm)."
      },
      {
        "id": "qa16",
        "q": "TG-142 kV imaging isocenter tolerance?",
        "a": "‚â§ 2 mm (monthly)",
        "c": [
          "‚â§ 0.5 mm",
          "‚â§ 1 mm",
          "‚â§ 2 mm (monthly)",
          "‚â§ 5 mm"
        ],
        "e": "Monthly kV/MV imaging-to-treatment isocenter coincidence must be within 2 mm for standard treatments.",
        "d": 5
      },
      {
        "id": "qa17",
        "q": "Star shot test checks?",
        "a": "Radiation isocentre size",
        "c": [
          "Output constancy",
          "Radiation isocentre size",
          "Beam energy",
          "Leaf speed"
        ],
        "e": "Multiple gantry angles expose a film/EPID at isocentre. The spoke pattern reveals the radiation isocentre diameter.",
        "d": 4
      },
      {
        "id": "qa18",
        "q": "Log file analysis for VMAT verifies?",
        "a": "Actual vs planned MLC/gantry/MU",
        "c": [
          "Patient setup only",
          "Actual vs planned MLC/gantry/MU",
          "CT number accuracy",
          "Beam energy spectrum"
        ],
        "e": "Machine log files record real-time gantry, MLC, and MU data ‚Äî can be compared to planned parameters for delivery verification.",
        "d": 5
      },
      {
        "id": "qa19",
        "q": "TG-142 annual output calibration tolerance?",
        "a": "¬± 1%",
        "c": [
          "¬± 0.5%",
          "¬± 1%",
          "¬± 2%",
          "¬± 3%"
        ],
        "e": "Full TRS-398/TG-51 calibration must agree within 1% of the stated output. This is the gold standard.",
        "d": 4
      },
      {
        "id": "qa20",
        "q": "Elekta daily QA device?",
        "a": "iViewGT / QC-3 phantom",
        "c": [
          "MPC beam check",
          "iViewGT / QC-3 phantom",
          "MapCHECK only",
          "Farmer chamber only"
        ],
        "e": "Elekta uses the QC-3 phantom with iViewGT EPID for daily constancy checks (output, flatness, symmetry).",
        "d": 5
      },
      {
        "id": "qa21",
        "q": "Portal dosimetry uses?",
        "a": "EPID as a 2D dosimeter",
        "c": [
          "Film at isocentre",
          "EPID as a 2D dosimeter",
          "Ion chamber array",
          "TLD chips"
        ],
        "e": "The EPID panel captures transmitted fluence and compares it to predicted images for IMRT/VMAT QA.",
        "d": 4
      },
      {
        "id": "qa22",
        "q": "ArcCHECK is?",
        "a": "Cylindrical diode array for VMAT QA",
        "c": [
          "CT calibration phantom",
          "Cylindrical diode array for VMAT QA",
          "Beam scanning device",
          "kV imaging phantom"
        ],
        "e": "Sun Nuclear ArcCHECK: 1386 diodes on a cylindrical surface for 3D composite dose verification of rotational plans.",
        "d": 4
      },
      {
        "id": "qa23",
        "q": "TG-142 gantry angle tolerance (daily)?",
        "a": "¬± 1¬∞",
        "c": [
          "¬± 0.5¬∞",
          "¬± 1¬∞",
          "¬± 2¬∞",
          "¬± 3¬∞"
        ],
        "e": "Digital gantry readout must agree with actual angle within ¬±1¬∞ for daily checks.",
        "d": 4
      },
      {
        "id": "qa24",
        "q": "Flatness definition (IEC)?",
        "a": "(Dmax-Dmin)/(Dmax+Dmin)√ó100%",
        "c": [
          "Dmax / Dcentral axis ratio",
          "(Dmax-Dmin)/(Dmax+Dmin)√ó100%",
          "D80% / D20% dose ratio",
          "Dcentre / Dedge at 80%"
        ],
        "e": "Measured in the flattened region (80% of field width). Monthly tolerance typically ¬± 2%.",
        "d": 6
      },
      {
        "id": "qa25",
        "q": "Symmetry definition?",
        "a": "Max symmetric point pair ratio",
        "c": [
          "Overall Dmax / Dmin ratio",
          "Max symmetric point pair ratio",
          "Left versus right output",
          "Cross-plane flatness value"
        ],
        "e": "Ratio of dose at symmetric points about the central axis. Monthly tolerance typically ¬± 2-3%.",
        "d": 5
      },
      {
        "id": "qa26",
        "q": "Winston-Lutz test frequency?",
        "a": "Monthly (daily for SRS)",
        "c": [
          "Annual only",
          "Monthly (daily for SRS)",
          "Weekly",
          "Per-patient"
        ],
        "e": "Monthly per TG-142 for standard use. Daily recommended when SRS/SRT patients are being treated.",
        "d": 4
      },
      {
        "id": "qa27",
        "q": "CALC: IMRT gamma 3%/3mm result: 520 pass out of 560 points. Pass rate?",
        "a": "92.9%",
        "c": [
          "90.0%",
          "92.9%",
          "95.0%",
          "97.1%"
        ],
        "e": "520/560 √ó 100 = 92.9%. Below TG-218 universal tolerance of 95% ‚Äî investigation required but above 90% action limit.",
        "d": 5
      },
      {
        "id": "qa28",
        "q": "Couch position tolerance (TG-142)?",
        "a": "¬± 2 mm / ¬± 1¬∞",
        "c": [
          "¬± 1 mm / ¬± 0.5¬∞",
          "¬± 2 mm / ¬± 1¬∞",
          "¬± 5 mm / ¬± 2¬∞",
          "¬± 3 mm / ¬± 1.5¬∞"
        ],
        "e": "Monthly verification of couch translational (¬± 2 mm) and rotational (¬± 1¬∞) accuracy.",
        "d": 5
      },
      {
        "id": "qa29",
        "q": "Baseline shift in output constancy indicates?",
        "a": "Component degradation or calibration drift",
        "c": [
          "Normal expected daily variation",
          "Component degradation or calibration drift",
          "Ambient temperature change only",
          "Measurement detector failure"
        ],
        "e": "Gradual output trends may indicate target/waveguide aging, magnetron changes, or chamber degradation. Investigate before it exceeds tolerance.",
        "d": 6
      },
      {
        "id": "qa30",
        "q": "Independent MU check purpose?",
        "a": "Verify TPS MU calculation independently",
        "c": [
          "Replace patient-specific QA",
          "Verify TPS MU calculation independently",
          "Check machine output",
          "Validate CT calibration"
        ],
        "e": "Second-check calculation using independent algorithm or hand calculation. Catches TPS input and modelling errors.",
        "d": 4
      }
    ],
    "equip": [
      {
        "id": "eq01",
        "q": "TrueBeam 10 FFF dose rate?",
        "a": "2400 MU/min",
        "c": [
          "800 MU/min",
          "1400 MU/min",
          "2400 MU/min",
          "600 MU/min"
        ],
        "e": "Highest clinical dose rate ‚Äî enables fast SRS/SBRT treatments."
      },
      {
        "id": "eq02",
        "q": "Halcyon architecture?",
        "a": "O-ring (bore)",
        "c": [
          "C-arm",
          "O-ring (bore)",
          "Gantry-free",
          "Robotic arm"
        ],
        "e": "Enclosed O-ring gantry: faster rotation but limits non-coplanar access."
      },
      {
        "id": "eq03",
        "q": "Halcyon electrons?",
        "a": "No ‚Äî 6 FFF only",
        "c": [
          "6, 9, 12 MeV",
          "6 MeV only",
          "No ‚Äî 6 FFF only",
          "Optional"
        ],
        "e": "Only 6 FFF photons. No electron beams, no energy selection."
      },
      {
        "id": "eq04",
        "q": "Halcyon beam model?",
        "a": "Pre-configured (golden)",
        "c": [
          "User-configured",
          "Pre-configured (golden)",
          "No model needed",
          "Monte Carlo"
        ],
        "e": "Varian provides a pre-validated 'golden' beam dataset. Limited user tuning."
      },
      {
        "id": "eq05",
        "q": "Millennium 120 central leaf width?",
        "a": "5 mm",
        "c": [
          "2.5 mm",
          "5 mm",
          "7.5 mm",
          "10 mm"
        ],
        "e": "Central 20 pairs at 5 mm, outer 20 pairs at 10 mm."
      },
      {
        "id": "eq06",
        "q": "HD120 central leaf width?",
        "a": "2.5 mm",
        "c": [
          "2.5 mm",
          "5 mm",
          "1 mm",
          "3 mm"
        ],
        "e": "32 central pairs at 2.5 mm ‚Äî superior conformity for small SRS targets."
      },
      {
        "id": "eq07",
        "q": "Halcyon gantry speed?",
        "a": "4 RPM",
        "c": [
          "1 RPM",
          "2 RPM",
          "4 RPM",
          "6 RPM"
        ],
        "e": "4√ó faster than TrueBeam (1 RPM). Rapid VMAT but coplanar only."
      },
      {
        "id": "eq08",
        "q": "Halcyon leaf transmission?",
        "a": "~0.4%",
        "c": [
          "~0.4%",
          "~1.4%",
          "~2.5%",
          "~5%"
        ],
        "e": "Dual-layer SX2 MLC stacks two offset banks, reducing leakage vs single-layer."
      },
      {
        "id": "eq09",
        "q": "Millennium leaf transmission?",
        "a": "~1.4%",
        "c": [
          "~0.4%",
          "~1.4%",
          "~2.5%",
          "~5%"
        ],
        "e": "Single-layer tungsten. Higher leakage than SX2 but within tolerance."
      },
      {
        "id": "eq10",
        "q": "ARIA is?",
        "a": "Oncology information system",
        "c": [
          "Eclipse plugin",
          "Oncology information system",
          "MLC tool",
          "QA phantom"
        ],
        "e": "Manages patient data, scheduling, and record & verify."
      },
      {
        "id": "eq11",
        "q": "Halcyon max field?",
        "a": "28 √ó 28 cm¬≤",
        "c": [
          "20 √ó 20 cm¬≤",
          "28 √ó 28 cm¬≤",
          "40 √ó 40 cm¬≤",
          "36 √ó 36 cm¬≤"
        ],
        "e": "Bore geometry limits field size. Insufficient for some large palliative fields."
      },
      {
        "id": "eq12",
        "q": "TrueBeam max field?",
        "a": "40 √ó 40 cm¬≤",
        "c": [
          "28 √ó 28 cm¬≤",
          "36 √ó 36 cm¬≤",
          "40 √ó 40 cm¬≤",
          "30 √ó 30 cm¬≤"
        ],
        "e": "C-arm allows full 40 √ó 40 ‚Äî handles all standard and large-field techniques."
      },
      {
        "id": "eq13",
        "q": "Ethos is?",
        "a": "Adaptive RT on Halcyon",
        "c": [
          "New TPS",
          "Adaptive RT on Halcyon",
          "kV upgrade",
          "MLC type"
        ],
        "e": "AI auto-contouring for online adaptive replanning, built on Halcyon hardware."
      },
      {
        "id": "eq14",
        "q": "TrueBeam 6 FFF dose rate?",
        "a": "1400 MU/min",
        "c": [
          "800 MU/min",
          "1400 MU/min",
          "2400 MU/min",
          "600 MU/min"
        ],
        "e": "Commonly used for breast and abdominal SBRT."
      },
      {
        "id": "eq15",
        "q": "Halcyon: non-coplanar arcs?",
        "a": "No ‚Äî coplanar only",
        "c": [
          "Yes",
          "No ‚Äî coplanar only",
          "With upgrade",
          "Only in Ethos"
        ],
        "e": "O-ring design prevents couch kicks ‚Äî unsuitable for intracranial SRS."
      },
      {
        "id": "eq16",
        "q": "Elekta Versa HD max dose rate (FFF)?",
        "a": "2200 MU/min (10 FFF)",
        "c": [
          "1400 MU/min",
          "2200 MU/min (10 FFF)",
          "2400 MU/min",
          "600 MU/min"
        ],
        "e": "Elekta Versa HD offers FFF at 6 and 10 MV. 10 FFF reaches 2200 MU/min.",
        "d": 5
      },
      {
        "id": "eq17",
        "q": "Elekta Agility MLC leaf width?",
        "a": "5 mm (all 160 leaves)",
        "c": [
          "2.5 mm",
          "5 mm (all 160 leaves)",
          "10 mm",
          "Variable 5/10 mm"
        ],
        "e": "Agility has 160 leaves all at 5 mm width ‚Äî uniform resolution across the full 40 cm field.",
        "d": 4
      },
      {
        "id": "eq18",
        "q": "Waveguide function in a linac?",
        "a": "Accelerate electrons with RF",
        "c": [
          "Flatten the beam profile",
          "Accelerate electrons with RF",
          "Collimate treatment beam",
          "Generate bremsstrahlung X-rays"
        ],
        "e": "Standing or travelling wave accelerating structure uses RF (typically 3 GHz) to push electrons to MeV energies.",
        "d": 4
      },
      {
        "id": "eq19",
        "q": "Magnetron vs klystron?",
        "a": "Magnetron generates, klystron amplifies RF",
        "c": [
          "Both generate RF",
          "Magnetron generates, klystron amplifies RF",
          "Klystron generates, magnetron amplifies",
          "They are interchangeable"
        ],
        "e": "Magnetrons are cheaper (lower energy linacs). Klystrons amplify an RF signal ‚Äî used in high-energy machines needing stable output.",
        "d": 6
      },
      {
        "id": "eq20",
        "q": "Bending magnet purpose?",
        "a": "Redirect electrons to isocentre",
        "c": [
          "Flatten the beam profile",
          "Redirect electrons to isocentre",
          "Generate bremsstrahlung photons",
          "Focus electron beam tightly"
        ],
        "e": "270¬∞ achromatic bending magnets redirect and energy-select the electron beam in compact linac heads.",
        "d": 5
      },
      {
        "id": "eq21",
        "q": "Target material for X-ray production?",
        "a": "Tungsten (high Z)",
        "c": [
          "Copper",
          "Aluminium",
          "Tungsten (high Z)",
          "Lead"
        ],
        "e": "High-Z tungsten maximises bremsstrahlung yield. Also has a high melting point for thermal handling.",
        "d": 3
      },
      {
        "id": "eq22",
        "q": "Flattening filter purpose?",
        "a": "Produce uniform beam profile",
        "c": [
          "Increase the dose rate",
          "Produce uniform beam profile",
          "Remove neutron contamination",
          "Reduce beam energy spread"
        ],
        "e": "Conical metal filter preferentially attenuates the central beam peak to produce a flat dose profile.",
        "d": 3
      },
      {
        "id": "eq23",
        "q": "Monitor chamber function?",
        "a": "Real-time output/symmetry monitoring",
        "c": [
          "Patient dose measurement device",
          "Real-time output/symmetry monitoring",
          "Beam energy measurement system",
          "MLC position readback sensor"
        ],
        "e": "Dual sealed ion chambers continuously monitor output (MU) and beam symmetry/flatness during treatment. Beam interlocks if out of tolerance.",
        "d": 4
      },
      {
        "id": "eq24",
        "q": "EPID detector material?",
        "a": "Amorphous silicon (a-Si)",
        "c": [
          "NaI(Tl)",
          "Amorphous silicon (a-Si)",
          "Film cassette",
          "CdZnTe"
        ],
        "e": "a-Si flat panel with Gd‚ÇÇO‚ÇÇS scintillator converts MV X-rays to visible light then to electrical signal for portal imaging.",
        "d": 5
      },
      {
        "id": "eq25",
        "q": "Varian RapidArc is?",
        "a": "Single-arc VMAT delivery",
        "c": [
          "Step-and-shoot IMRT",
          "Single-arc VMAT delivery",
          "Electron therapy mode",
          "Tomotherapy technique"
        ],
        "e": "Varian's implementation of VMAT ‚Äî continuous gantry rotation with variable MLC, dose rate, and gantry speed.",
        "d": 3
      },
      {
        "id": "eq26",
        "q": "TomoTherapy delivery method?",
        "a": "Helical fan beam with binary MLC",
        "c": [
          "C-arm with standard MLC",
          "Helical fan beam with binary MLC",
          "Robotic arm delivery",
          "Static parallel opposed beams"
        ],
        "e": "Accuray TomoTherapy delivers IMRT via a rotating fan beam and binary (open/closed) MLC in a helical pattern, like a CT scanner.",
        "d": 5
      },
      {
        "id": "eq27",
        "q": "CBCT imaging dose (typical)?",
        "a": "~20-50 mGy per scan",
        "c": [
          "~0.1 mGy",
          "~1-5 mGy",
          "~20-50 mGy per scan",
          "~200 mGy"
        ],
        "e": "kV CBCT delivers non-trivial imaging dose per fraction. Must be justified and included in cumulative dose assessment.",
        "d": 5
      },
      {
        "id": "eq28",
        "q": "Surface guided radiation therapy (SGRT) uses?",
        "a": "3D optical surface imaging for setup",
        "c": [
          "Implanted fiducial markers",
          "3D optical surface imaging for setup",
          "Ultrasound body scanning",
          "External laser measurements"
        ],
        "e": "Systems like AlignRT/IDENTIFY project and track the patient surface optically ‚Äî enables markerless setup and intra-fraction monitoring.",
        "d": 4
      },
      {
        "id": "eq29",
        "q": "Electron applicator function?",
        "a": "Collimate and define electron field",
        "c": [
          "Accelerate electrons",
          "Collimate and define electron field",
          "Flatten electron beam",
          "Monitor dose output"
        ],
        "e": "Electron cones/applicators are attached to the linac head to define the treatment field and reduce scatter contamination.",
        "d": 3
      },
      {
        "id": "eq30",
        "q": "6DOF couch correction means?",
        "a": "3 translations + 3 rotations",
        "c": [
          "6 translations only",
          "3 translations + 3 rotations",
          "6 rotations only",
          "6 gantry angles"
        ],
        "e": "Six Degrees of Freedom: lateral, longitudinal, vertical shifts plus pitch, roll, yaw rotations for precise patient repositioning.",
        "d": 3
      }
    ],
    "eclipse": [
      {
        "id": "ec01",
        "q": "AcurosXB solves?",
        "a": "LBTE",
        "c": [
          "Schr√∂dinger",
          "LBTE",
          "Monte Carlo",
          "Pencil beam"
        ],
        "e": "Linear Boltzmann Transport Equation ‚Äî deterministic solver for photon and electron transport in heterogeneous media."
      },
      {
        "id": "ec02",
        "q": "AAA limitation in lung?",
        "a": "Overestimates 5-15%",
        "c": [
          "Underestimates 5-15%",
          "Overestimates 5-15%",
          "No limitation",
          "Crashes"
        ],
        "e": "AAA uses 1D density scaling ‚Äî poor electron transport at tissue-lung interfaces."
      },
      {
        "id": "ec03",
        "q": "AcurosXB dose reporting modes?",
        "a": "D_m and D_w",
        "c": [
          "D_m only",
          "D_w only",
          "D_m and D_w",
          "Relative only"
        ],
        "e": "Dose-to-medium is physically correct; dose-to-water allows comparison with older algorithms."
      },
      {
        "id": "ec04",
        "q": "D_m vs D_w: biggest difference in?",
        "a": "Bone (~3-5%)",
        "c": [
          "Water",
          "Lung",
          "Bone (~3-5%)",
          "Air"
        ],
        "e": "Bone has very different stopping power ratios. D_m and D_w converge in soft tissue."
      },
      {
        "id": "ec05",
        "q": "Eclipse default grid size?",
        "a": "2.5 mm",
        "c": [
          "1 mm",
          "2 mm",
          "2.5 mm",
          "5 mm"
        ],
        "e": "Must be reduced to ‚â§ 2 mm for SBRT and ‚â§ 1 mm for SRS."
      },
      {
        "id": "ec06",
        "q": "DLG measurement method?",
        "a": "Sweeping gap",
        "c": [
          "Picket fence",
          "Sweeping gap",
          "Star shot",
          "Output ratio"
        ],
        "e": "Dynamic sliding windows with known gap widths. Extrapolate dose to zero gap = DLG."
      },
      {
        "id": "ec07",
        "q": "NTO in Eclipse?",
        "a": "Normal Tissue Objective",
        "c": [
          "New Treatment Optimiser",
          "Normal Tissue Objective",
          "Nominal Target Outline",
          "Non-Target OAR"
        ],
        "e": "Automatically reduces dose to all non-target tissue. Use it in every optimisation."
      },
      {
        "id": "ec08",
        "q": "Van Herk margin formula?",
        "a": "M = 2.5Œ£ + 0.7œÉ",
        "c": [
          "M = 2Œ£ + œÉ",
          "M = 2.5Œ£ + 0.7œÉ",
          "M = 3Œ£ + 0.5œÉ",
          "M = Œ£ + 2œÉ"
        ],
        "e": "Ensures minimum CTV dose ‚â• 95% for 90% of patients. Œ£ = systematic, œÉ = random error SD."
      },
      {
        "id": "ec09",
        "q": "Jaw tracking in VMAT does?",
        "a": "Reduces scatter/leakage",
        "c": [
          "Speeds delivery",
          "Reduces scatter/leakage",
          "Improves imaging",
          "Locks jaws"
        ],
        "e": "Jaws follow MLC aperture dynamically. Enable for SBRT to improve OAR sparing."
      },
      {
        "id": "ec10",
        "q": "HI formula?",
        "a": "(D2% ‚àí D98%) / D50%",
        "c": [
          "D50% / Dprescribed",
          "(D2% ‚àí D98%) / D50%",
          "Dmax / Dmin",
          "D95% / D5%"
        ],
        "e": "Lower = more uniform dose. Some inhomogeneity acceptable in SRT."
      },
      {
        "id": "ec11",
        "q": "VMAT vs IMRT delivery?",
        "a": "VMAT is faster",
        "c": [
          "IMRT is faster",
          "VMAT is faster",
          "Same speed",
          "Depends on energy"
        ],
        "e": "Continuous rotation with simultaneous modulation. Typically 2-3 min vs 10-15 for step-and-shoot."
      },
      {
        "id": "ec12",
        "q": "CT calibration curve maps?",
        "a": "HU to electron density",
        "c": [
          "HU to dose",
          "HU to electron density",
          "Dose to MU",
          "MU to HU"
        ],
        "e": "Site-specific HU-to-density table. Wrong curve = systematic dose errors in every plan."
      },
      {
        "id": "ec13",
        "q": "Wrong CT curve causes?",
        "a": "Systematic dose errors",
        "c": [
          "Nothing",
          "Systematic dose errors",
          "Image artefacts only",
          "MLC errors"
        ],
        "e": "Overestimate density ‚Üí underestimate dose. Most critical in lung and bone."
      },
      {
        "id": "ec14",
        "q": "Ring structure controls?",
        "a": "Dose falloff gradient",
        "c": [
          "Target coverage",
          "Dose falloff gradient",
          "Beam shaping",
          "MLC speed"
        ],
        "e": "Donut around PTV for optimisation. Tighter ring = steeper falloff."
      },
      {
        "id": "ec15",
        "q": "Plan modulation factor?",
        "a": "Total MU / prescribed cGy",
        "c": [
          "Dose rate / MU",
          "Total MU / prescribed cGy",
          "Arcs √ó segments",
          "Field size ratio"
        ],
        "e": "High modulation (>3-4√ó) = complex MLC motion, higher delivery uncertainty."
      },
      {
        "id": "ec16",
        "q": "Photon Optimizer (PO) in Eclipse does?",
        "a": "VMAT inverse optimisation",
        "c": [
          "Forward planning only",
          "VMAT inverse optimisation",
          "Electron beam planning",
          "CT reconstruction"
        ],
        "e": "PO optimises simultaneously over MLC, gantry speed, and dose rate for arc-based IMRT/VMAT plans.",
        "d": 4
      },
      {
        "id": "ec17",
        "q": "Multi-resolution dose calculation (MRDC)?",
        "a": "Coarse grid far, fine grid near target",
        "c": [
          "Same resolution grid everywhere",
          "Coarse grid far, fine grid near target",
          "Calculates only inside the PTV",
          "Random Monte Carlo sampling method"
        ],
        "e": "Speeds up optimisation by using fine grids near targets/OARs and coarser grids elsewhere.",
        "d": 5
      },
      {
        "id": "ec18",
        "q": "Bolus in Eclipse planning?",
        "a": "Increase surface dose with slab",
        "c": [
          "Compensate for air gap effect",
          "Increase surface dose with slab",
          "Correct CT image artefacts",
          "Modify beam energy spectrum"
        ],
        "e": "Bolus draws the dmax buildup region closer to the skin surface. Must be placed physically on the patient too.",
        "d": 3
      },
      {
        "id": "ec19",
        "q": "Structure margin expansion is?",
        "a": "Isotropic/anisotropic contour growth",
        "c": [
          "Dose calculation boundary limit",
          "Isotropic/anisotropic contour growth",
          "Treatment field size adjustment",
          "Calculation grid resolution change"
        ],
        "e": "CTV‚ÜíPTV margins can be uniform (isotropic) or direction-specific (anisotropic) to account for different error sources.",
        "d": 3
      },
      {
        "id": "ec20",
        "q": "Eclipse plan sum limitation?",
        "a": "Deformable registration needed for different CTs",
        "c": [
          "Cannot sum plans at all in Eclipse",
          "Deformable registration needed for different CTs",
          "Limited to combining only two plans",
          "Only available for photon beam plans"
        ],
        "e": "Summing plans on different CT datasets requires deformable image registration (DIR) to map dose between anatomies.",
        "d": 5
      },
      {
        "id": "ec21",
        "q": "DVH type: differential vs cumulative?",
        "a": "Cumulative: volume‚â•dose; Differential: volume at dose",
        "c": [
          "They display identical information always",
          "Cumulative: volume‚â•dose; Differential: volume at dose",
          "Differential DVH is always preferred clinically",
          "Cumulative DVH is never used in practice"
        ],
        "e": "Cumulative DVH (standard clinical use) shows what percentage of structure receives at least a given dose.",
        "d": 4
      },
      {
        "id": "ec22",
        "q": "PRV stands for?",
        "a": "Planning organ at Risk Volume",
        "c": [
          "Primary Radiation Volume",
          "Planning organ at Risk Volume",
          "Prescribed Reference Volume",
          "Peripheral Risk Vicinity"
        ],
        "e": "ICRU concept: OAR + margin for geometric uncertainty, analogous to CTV‚ÜíPTV for targets.",
        "d": 4
      },
      {
        "id": "ec23",
        "q": "ICRU 83 dose reporting recommendation?",
        "a": "D50% (median dose) to target",
        "c": [
          "Dmax to target",
          "D50% (median dose) to target",
          "Dmin to target",
          "Mean dose to target"
        ],
        "e": "ICRU 83 recommends reporting D50% (near-median) as the primary dose descriptor for IMRT plans.",
        "d": 5
      },
      {
        "id": "ec24",
        "q": "Heterogeneity correction importance?",
        "a": "Critical for lung/bone dose accuracy",
        "c": [
          "Only cosmetic improvement",
          "Critical for lung/bone dose accuracy",
          "Only for electron beams",
          "Not needed with modern TPS"
        ],
        "e": "Without heterogeneity corrections, lung tumour doses can be overestimated by 10-20%. AcurosXB handles this better than AAA.",
        "d": 5
      },
      {
        "id": "ec25",
        "q": "CALC: HI = (D2% ‚àí D98%)/D50%. D2%=72Gy, D98%=65Gy, D50%=70Gy. HI=?",
        "a": "0.10",
        "c": [
          "0.07",
          "0.10",
          "0.14",
          "0.20"
        ],
        "e": "HI = (72-65)/70 = 7/70 = 0.10. Lower values indicate more homogeneous dose. Typical VMAT plans achieve 0.05-0.15.",
        "d": 5
      },
      {
        "id": "ec26",
        "q": "Collimator angle optimisation helps?",
        "a": "Reduce T&G effect, improve OAR sparing",
        "c": [
          "Increase overall dose rate delivery",
          "Reduce T&G effect, improve OAR sparing",
          "Simplify plan delivery complexity",
          "Reduce total treatment time only"
        ],
        "e": "Rotating the collimator can align MLC travel direction to better spare critical structures and reduce interleaf leakage patterns.",
        "d": 6
      },
      {
        "id": "ec27",
        "q": "Dose volume constraint D95% ‚â• 95% means?",
        "a": "95% of volume receives ‚â• 95% Rx dose",
        "c": [
          "95% of dose delivered to 95% of OAR",
          "95% of volume receives ‚â• 95% Rx dose",
          "Maximum point dose limited to 95%",
          "95 Gy delivered to 95% of volume"
        ],
        "e": "Standard target coverage constraint: at least 95% of the PTV should receive 95% of the prescription dose.",
        "d": 3
      },
      {
        "id": "ec28",
        "q": "Couch model in Eclipse?",
        "a": "Accounts for couch attenuation in dose calc",
        "c": [
          "Only for collision detection",
          "Accounts for couch attenuation in dose calc",
          "Cosmetic display only",
          "Not available in Eclipse"
        ],
        "e": "Treatment couch structures model beam attenuation through the couch (~2-6% for posterior beams), improving dose accuracy.",
        "d": 4
      },
      {
        "id": "ec29",
        "q": "VMAT dual arc advantage over single arc?",
        "a": "More modulation, better OAR sparing",
        "c": [
          "Faster overall treatment time",
          "More modulation, better OAR sparing",
          "Lower total MU delivery needed",
          "Simpler patient-specific plan QA"
        ],
        "e": "Two arcs provide more modulation degrees of freedom, especially for complex targets like H&N with many OAR constraints.",
        "d": 4
      },
      {
        "id": "ec30",
        "q": "Plan complexity metrics include?",
        "a": "MCS, aperture irregularity, MU/cGy",
        "c": [
          "Only total monitor units count",
          "MCS, aperture irregularity, MU/cGy",
          "Only number of segments matters",
          "Only total treatment time ratio"
        ],
        "e": "Modulation Complexity Score (MCS), aperture irregularity, and MU/cGy ratio help predict deliverability and QA pass rates.",
        "d": 6
      }
    ],
    "dosimetry": [
      {
        "id": "do01",
        "q": "TRS-398 beam quality specifier?",
        "a": "TPR‚ÇÇ‚ÇÄ,‚ÇÅ‚ÇÄ",
        "c": [
          "%dd(10)x",
          "TPR‚ÇÇ‚ÇÄ,‚ÇÅ‚ÇÄ",
          "D‚ÇÅ‚ÇÄ/D‚ÇÇ‚ÇÄ",
          "PDD‚ÇÇ‚ÇÄ"
        ],
        "e": "Tissue-Phantom Ratio at 20 and 10 cm depth. Used to select k_Q."
      },
      {
        "id": "do02",
        "q": "N_D,w is?",
        "a": "Dose-to-water coefficient",
        "c": [
          "Neutron factor",
          "Dose-to-water coefficient",
          "Noise ratio",
          "Normalisation factor"
        ],
        "e": "Absorbed dose to water calibration coefficient, traceable to a primary standards lab."
      },
      {
        "id": "do03",
        "q": "Two-voltage technique measures?",
        "a": "Recombination (k_s)",
        "c": [
          "Energy",
          "Recombination (k_s)",
          "kV quality",
          "MLC positions"
        ],
        "e": "Measure at V and V/2 to quantify incomplete ion collection. Critical for FFF."
      },
      {
        "id": "do04",
        "q": "k_TP corrects for?",
        "a": "Temperature/pressure",
        "c": [
          "Beam quality",
          "Temperature/pressure",
          "Polarity",
          "Cable leakage"
        ],
        "e": "Air density varies with T and P. Must measure at time of calibration."
      },
      {
        "id": "do05",
        "q": "TRS-398 photon uncertainty?",
        "a": "~1.5%",
        "c": [
          "~0.5%",
          "~1.5%",
          "~3%",
          "~5%"
        ],
        "e": "Combined standard uncertainty of ~1.5% (1œÉ). The floor of our accuracy."
      },
      {
        "id": "do06",
        "q": "SA dosimetry protocol?",
        "a": "TRS-398",
        "c": [
          "TG-51",
          "TRS-398",
          "TRS-483",
          "TG-106"
        ],
        "e": "South Africa follows IAEA TRS-398. TG-51 is the North American equivalent."
      },
      {
        "id": "do07",
        "q": "TRS-398 vs TG-51: SA uses?",
        "a": "TRS-398",
        "c": [
          "TG-51",
          "TRS-398",
          "Both equally",
          "Neither"
        ],
        "e": "Both N_D,w-based. TRS-398 uses TPR‚ÇÇ‚ÇÄ,‚ÇÅ‚ÇÄ; TG-51 uses %dd(10)x."
      },
      {
        "id": "do08",
        "q": "k_Q depends on?",
        "a": "Beam quality & chamber type",
        "c": [
          "Temperature only",
          "Beam quality & chamber type",
          "Field size",
          "Depth"
        ],
        "e": "Tabulated per chamber model and beam quality. Corrects relative to Co-60 calibration."
      },
      {
        "id": "do09",
        "q": "Reference field for photon cal?",
        "a": "10 √ó 10 cm¬≤",
        "c": [
          "5 √ó 5 cm¬≤",
          "10 √ó 10 cm¬≤",
          "20 √ó 20 cm¬≤",
          "3 √ó 3 cm¬≤"
        ],
        "e": "Universal reference condition at SSD 100 cm or SAD 100 cm."
      },
      {
        "id": "do10",
        "q": "Reference depth (TRS-398)?",
        "a": "10 cm",
        "c": [
          "5 cm",
          "10 cm",
          "dmax",
          "20 cm"
        ],
        "e": "Deep enough to avoid contaminant electrons."
      },
      {
        "id": "do11",
        "q": "Polarity correction measures?",
        "a": "Charge collection asymmetry",
        "c": [
          "Temperature effect",
          "Charge collection asymmetry",
          "Stem leakage",
          "Cable loss"
        ],
        "e": "Reverse polarity and average. Corrects for stem and cable irradiation effects."
      },
      {
        "id": "do12",
        "q": "Why k_s matters more for FFF?",
        "a": "Higher dose-per-pulse",
        "c": [
          "Lower energy",
          "Higher dose-per-pulse",
          "Wider field",
          "More scatter"
        ],
        "e": "More dose per pulse ‚Üí more recombination ‚Üí larger correction."
      },
      {
        "id": "do13",
        "q": "Farmer chamber volume?",
        "a": "~0.6 cm¬≥",
        "c": [
          "~0.01 cm¬≥",
          "~0.1 cm¬≥",
          "~0.6 cm¬≥",
          "~1.0 cm¬≥"
        ],
        "e": "Standard reference chamber for absolute dosimetry. Too large for small fields (< 4√ó4 cm¬≤) ‚Äî use smaller detectors.",
        "d": 3
      },
      {
        "id": "do14",
        "q": "Parallel plate chamber use?",
        "a": "Electron beam dosimetry",
        "c": [
          "Photon beam only",
          "Electron beam dosimetry",
          "Neutron dosimetry",
          "kV dosimetry only"
        ],
        "e": "Thin entrance window minimises perturbation in electron beams. Required for electron energies where cylindrical chambers have too much perturbation.",
        "d": 4
      },
      {
        "id": "do15",
        "q": "CALC: Chamber reading 25.6 nC, N_D,w = 4.88 cGy/nC, k_Q = 0.993, k_TP = 1.005, k_s = 1.003, k_pol = 1.001. Dose?",
        "a": "123.5 cGy",
        "c": [
          "121.2 cGy",
          "123.5 cGy",
          "125.0 cGy",
          "128.3 cGy"
        ],
        "e": "D = M √ó N_D,w √ó k_Q √ó k_TP √ó k_s √ó k_pol = 25.6 √ó 4.88 √ó 0.993 √ó 1.005 √ó 1.003 √ó 1.001 ‚âà 123.5 cGy.",
        "d": 8
      },
      {
        "id": "do16",
        "q": "Electrometer function?",
        "a": "Measure ion chamber charge output",
        "c": [
          "Generate the radiation beam",
          "Measure ion chamber charge output",
          "Control linac dose rate output",
          "Display patient absorbed dose"
        ],
        "e": "High-sensitivity electrometer measures picocoulomb-level charges from ionisation chambers with high precision.",
        "d": 3
      },
      {
        "id": "do17",
        "q": "Cross-calibration procedure?",
        "a": "Calibrate field chamber against reference chamber",
        "c": [
          "Calibrate linac against Co-60",
          "Calibrate field chamber against reference chamber",
          "Calibrate TPS against measurements",
          "Calibrate CT scanner HU values"
        ],
        "e": "A field chamber used daily is cross-calibrated against the primary reference chamber to establish its own calibration coefficient.",
        "d": 5
      },
      {
        "id": "do18",
        "q": "PDD depends on?",
        "a": "Energy, field size, SSD, depth",
        "c": [
          "Energy only",
          "Energy and depth only",
          "Energy, field size, SSD, depth",
          "Field size only"
        ],
        "e": "Percentage Depth Dose varies with all four parameters. Larger fields and higher energies shift dmax deeper.",
        "d": 4
      },
      {
        "id": "do19",
        "q": "TMR vs PDD advantage?",
        "a": "TMR is SSD-independent",
        "c": [
          "PDD is SSD-independent",
          "TMR is SSD-independent",
          "They are identical",
          "TMR only works for electrons"
        ],
        "e": "Tissue-Maximum Ratio is defined at SAD setup and doesn't depend on SSD ‚Äî preferred for isocentric calculations.",
        "d": 5
      },
      {
        "id": "do20",
        "q": "Output factor (S_cp)?",
        "a": "Dose ratio: field size vs 10√ó10 ref",
        "c": [
          "Absolute dose calibration factor",
          "Dose ratio: field size vs 10√ó10 ref",
          "Beam energy quality indicator",
          "Patient scatter correction only"
        ],
        "e": "Total scatter factor S_cp = S_c √ó S_p combines collimator scatter (S_c) and phantom scatter (S_p) relative to reference field.",
        "d": 5
      },
      {
        "id": "do21",
        "q": "Film dosimetry advantage?",
        "a": "High-resolution 2D dose mapping",
        "c": [
          "Energy-independent dose reading",
          "High-resolution 2D dose mapping",
          "Real-time immediate readout",
          "No calibration curve needed"
        ],
        "e": "Radiochromic film (EBT3/EBT-XD) provides sub-mm spatial resolution 2D dose distributions. Needs careful calibration and handling.",
        "d": 4
      },
      {
        "id": "do22",
        "q": "Alanine dosimetry used for?",
        "a": "Independent postal dose audit (EPR)",
        "c": [
          "Daily output constancy checks",
          "Independent postal dose audit (EPR)",
          "Patient in-vivo dose measurement",
          "Small-field output measurement"
        ],
        "e": "Alanine pellets read by EPR spectroscopy ‚Äî used by IAEA/NPL for postal dose audit programs. Very stable, near water-equivalent.",
        "d": 6
      },
      {
        "id": "do23",
        "q": "In-vivo dosimetry purpose?",
        "a": "Verify dose delivered to patient",
        "c": [
          "Replace treatment planning",
          "Verify dose delivered to patient",
          "Calibrate the linac",
          "Check room shielding"
        ],
        "e": "Detectors (diodes, MOSFETs, OSLDs) placed on or in the patient measure actual delivered dose as an independent safety check.",
        "d": 3
      },
      {
        "id": "do24",
        "q": "Diode vs ion chamber for relative dosimetry?",
        "a": "Diode has higher sensitivity per volume",
        "c": [
          "Ion chamber is more sensitive",
          "Diode has higher sensitivity per volume",
          "They are equivalent",
          "Diode cannot measure dose"
        ],
        "e": "Silicon diodes are ~18,000√ó more sensitive per unit volume than air ‚Äî ideal for relative measurements in small volumes.",
        "d": 5
      },
      {
        "id": "do25",
        "q": "Water phantom scanning system measures?",
        "a": "PDD, profiles, output factors",
        "c": [
          "Patient dose only",
          "PDD, profiles, output factors",
          "Room scatter only",
          "Beam energy spectrum"
        ],
        "e": "3D water tank with motorised detector scanning provides beam data for TPS commissioning: depth doses, cross-profiles, and output factors.",
        "d": 3
      },
      {
        "id": "do26",
        "q": "CALC: k_TP = (273.15 + T)/(273.15 + 22) √ó 101.33/P. At T=24¬∞C, P=100.5 kPa, k_TP=?",
        "a": "1.014",
        "c": [
          "0.986",
          "1.000",
          "1.014",
          "1.028"
        ],
        "e": "k_TP = (297.15/295.15) √ó (101.33/100.5) = 1.00678 √ó 1.00826 ‚âà 1.014. Warmer air is less dense ‚Üí larger correction.",
        "d": 7
      },
      {
        "id": "do27",
        "q": "Effective point of measurement for cylindrical chamber?",
        "a": "Shifted upstream by 0.6 √ó cavity radius",
        "c": [
          "Located at geometric cavity centre",
          "Shifted upstream by 0.6 √ó cavity radius",
          "Located at chamber entrance tip",
          "Shifted downstream by 0.6 √ó radius"
        ],
        "e": "The effective point of measurement is shifted 0.6 times the cavity radius toward the source to account for the gradient effect.",
        "d": 6
      }
    ],
    "nucmed": [
      {
        "id": "nm01",
        "q": "Tc-99m half-life?",
        "a": "6.01 hours",
        "c": [
          "2 hours",
          "6.01 hours",
          "12 hours",
          "73 hours"
        ],
        "e": "Ideal for imaging: long enough for prep and scanning, short enough for low patient dose."
      },
      {
        "id": "nm02",
        "q": "Tc-99m gamma energy?",
        "a": "140 keV",
        "c": [
          "80 keV",
          "140 keV",
          "364 keV",
          "511 keV"
        ],
        "e": "Optimal for NaI(Tl) detection ‚Äî good tissue penetration with efficient collimation."
      },
      {
        "id": "nm03",
        "q": "PET annihilation photon energy?",
        "a": "511 keV",
        "c": [
          "140 keV",
          "364 keV",
          "511 keV",
          "662 keV"
        ],
        "e": "Positron + electron ‚Üí two 511 keV photons at 180¬∞ ‚Äî basis of PET coincidence detection."
      },
      {
        "id": "nm04",
        "q": "F-18 FDG half-life?",
        "a": "110 min",
        "c": [
          "20 min",
          "68 min",
          "110 min",
          "6 hours"
        ],
        "e": "Long enough for synthesis, transport, uptake and scanning. Most widely used PET tracer."
      },
      {
        "id": "nm05",
        "q": "I-131 half-life?",
        "a": "8.02 days",
        "c": [
          "6 hours",
          "2.7 days",
          "8.02 days",
          "14 days"
        ],
        "e": "Used for thyroid ablation therapy. Long half-life requires radiation protection precautions."
      },
      {
        "id": "nm06",
        "q": "I-131 primary gamma energy?",
        "a": "364 keV",
        "c": [
          "140 keV",
          "364 keV",
          "511 keV",
          "662 keV"
        ],
        "e": "Also emits beta particles (therapeutic). The 364 keV gamma enables post-therapy imaging."
      },
      {
        "id": "nm07",
        "q": "Gamma camera collimator (general)?",
        "a": "Parallel hole",
        "c": [
          "Pinhole",
          "Parallel hole",
          "Fan beam",
          "Cone beam"
        ],
        "e": "Most common general-purpose. Pinhole for thyroid; fan beam for brain SPECT."
      },
      {
        "id": "nm08",
        "q": "SPECT stands for?",
        "a": "Single Photon Emission CT",
        "c": [
          "Standard Photon Emission CT",
          "Single Photon Emission CT",
          "Spectral Photon Enhanced CT",
          "Single Positron Emission CT"
        ],
        "e": "Camera rotates to acquire projections, reconstructed into 3D."
      },
      {
        "id": "nm09",
        "q": "PET spatial resolution (clinical)?",
        "a": "4-6 mm",
        "c": [
          "1-2 mm",
          "4-6 mm",
          "10-12 mm",
          "15-20 mm"
        ],
        "e": "Limited by positron range, photon non-collinearity, and crystal size."
      },
      {
        "id": "nm10",
        "q": "Mo-99 generator is called?",
        "a": "Moly cow",
        "c": [
          "Technetium trap",
          "Moly cow",
          "Isotope mill",
          "Gamma source"
        ],
        "e": "'Milked' daily. Mo-99 (66h) decays to Tc-99m on an alumina column."
      },
      {
        "id": "nm11",
        "q": "PET detector material (common)?",
        "a": "LSO / LYSO",
        "c": [
          "NaI(Tl)",
          "LSO / LYSO",
          "BGO only",
          "CsI(Tl)"
        ],
        "e": "Fast timing, high light output, good stopping power for 511 keV."
      },
      {
        "id": "nm12",
        "q": "Gamma camera detector material?",
        "a": "NaI(Tl)",
        "c": [
          "NaI(Tl)",
          "LSO",
          "CdZnTe",
          "Si(Li)"
        ],
        "e": "Thallium-doped sodium iodide: excellent light yield at 140 keV."
      },
      {
        "id": "nm13",
        "q": "MUGA scan assesses?",
        "a": "Cardiac ejection fraction",
        "c": [
          "Lung perfusion",
          "Cardiac ejection fraction",
          "Bone density",
          "Thyroid uptake"
        ],
        "e": "Tc-99m-labelled RBCs imaged through cardiac cycle to calculate LVEF."
      },
      {
        "id": "nm14",
        "q": "Ga-68 half-life?",
        "a": "68 min",
        "c": [
          "13 min",
          "68 min",
          "110 min",
          "6 hours"
        ],
        "e": "Generator-produced. Enables PET without a cyclotron ‚Äî used for PSMA and DOTATATE."
      },
      {
        "id": "nm15",
        "q": "Lu-177 therapy treats?",
        "a": "Neuroendocrine/prostate (PSMA)",
        "c": [
          "Thyroid cancer ablation",
          "Neuroendocrine/prostate (PSMA)",
          "Breast cancer treatment",
          "Brain metastases therapy"
        ],
        "e": "Lutathera (DOTATATE) and Pluvicto (PSMA) ‚Äî landmark theranostic treatments."
      },
      {
        "id": "nm16",
        "q": "Theranostics concept?",
        "a": "Same molecule for diagnosis and therapy",
        "c": [
          "Combined CT and MRI scan",
          "Same molecule for diagnosis and therapy",
          "Dual-energy imaging technique",
          "Therapeutic ultrasound"
        ],
        "e": "Pair diagnostic isotope (e.g., Ga-68) with therapeutic isotope (e.g., Lu-177) on the same targeting molecule. See-then-treat paradigm.",
        "d": 4
      },
      {
        "id": "nm17",
        "q": "SUV in PET stands for?",
        "a": "Standardized Uptake Value",
        "c": [
          "Signal Uniformity Value",
          "Standardized Uptake Value",
          "Spatial Unit Variance",
          "Spectral Uptake Verification"
        ],
        "e": "SUV normalises tracer uptake by injected activity and body weight. SUV > 2.5 often suggests malignancy for FDG-PET.",
        "d": 4
      },
      {
        "id": "nm18",
        "q": "Time-of-flight (TOF) PET advantage?",
        "a": "Better signal-to-noise ratio",
        "c": [
          "Higher spatial resolution",
          "Better signal-to-noise ratio",
          "Faster scan acquisition",
          "Lower injected activity"
        ],
        "e": "TOF localises the annihilation event along the LOR using timing differences, improving effective sensitivity and SNR.",
        "d": 6
      },
      {
        "id": "nm19",
        "q": "Ra-223 therapy mechanism?",
        "a": "Alpha emitter targeting bone metastases",
        "c": [
          "Beta emitter for thyroid",
          "Alpha emitter targeting bone metastases",
          "Gamma emitter for imaging",
          "Neutron therapy for brain"
        ],
        "e": "Radium-223 (Xofigo) is a calcium-mimetic alpha emitter that incorporates into bone remodelling sites ‚Äî treats castration-resistant prostate cancer bone mets.",
        "d": 5
      },
      {
        "id": "nm20",
        "q": "Gamma camera energy window for Tc-99m?",
        "a": "¬±10-15% around 140 keV",
        "c": [
          "¬±5% around 80 keV",
          "¬±10-15% around 140 keV",
          "¬±20% around 511 keV",
          "¬±10% around 364 keV"
        ],
        "e": "Photopeak window centered at 140 keV captures primary photons while rejecting scatter.",
        "d": 4
      },
      {
        "id": "nm21",
        "q": "CZT detector advantage over NaI?",
        "a": "Better energy resolution, compact size",
        "c": [
          "Cheaper manufacturing and cost",
          "Better energy resolution, compact size",
          "Higher scintillation light output",
          "Larger available crystal sizes"
        ],
        "e": "Cadmium Zinc Telluride (CZT) is a semiconductor ‚Äî direct conversion with superior energy resolution (~5% vs 10% for NaI). Used in cardiac SPECT.",
        "d": 6
      },
      {
        "id": "nm22",
        "q": "Y-90 therapy application?",
        "a": "Radioembolisation for liver tumours",
        "c": [
          "Thyroid ablation treatment",
          "Radioembolisation for liver tumours",
          "Bone pain palliation therapy",
          "Lymphoma targeted treatment"
        ],
        "e": "Y-90 microspheres (SIR-Spheres/TheraSphere) are injected into hepatic artery to deliver localised beta radiation to liver tumours.",
        "d": 5
      },
      {
        "id": "nm23",
        "q": "Dose calibrator measures?",
        "a": "Assay radiopharmaceutical activity",
        "c": [
          "Measure area dose rate levels",
          "Assay radiopharmaceutical activity",
          "Calculate patient absorbed dose",
          "Determine beam energy level"
        ],
        "e": "Well-type ionisation chamber calibrated in Bq/MBq to assay radiopharmaceutical activity before patient administration.",
        "d": 3
      },
      {
        "id": "nm24",
        "q": "CALC: Tc-99m initial activity 800 MBq. Activity after 12 hours?",
        "a": "200 MBq",
        "c": [
          "100 MBq",
          "200 MBq",
          "400 MBq",
          "600 MBq"
        ],
        "e": "12 hours = 2 half-lives (T¬Ω = 6.01 hr). A = 800 √ó (¬Ω)¬≤ = 800/4 = 200 MBq.",
        "d": 4
      },
      {
        "id": "nm25",
        "q": "MIBG scan target?",
        "a": "Neuroendocrine tumours (phaeo/neuroblastoma)",
        "c": [
          "Bone metastases and skeletal lesions",
          "Neuroendocrine tumours (phaeo/neuroblastoma)",
          "Cardiac function and wall motion",
          "Lung perfusion and ventilation scan"
        ],
        "e": "I-123/I-131 MIBG (meta-iodobenzylguanidine) is taken up by adrenergic tissue ‚Äî images and treats neuroblastoma and phaeochromocytoma.",
        "d": 5
      },
      {
        "id": "nm26",
        "q": "Attenuation correction in PET uses?",
        "a": "CT-based attenuation map",
        "c": [
          "No correction needed",
          "CT-based attenuation map",
          "Ge-68 transmission scan only",
          "Patient weight estimate"
        ],
        "e": "PET/CT uses the CT data to generate attenuation correction factors for each LOR, improving quantitative accuracy.",
        "d": 4
      },
      {
        "id": "nm27",
        "q": "Scatter window method in SPECT?",
        "a": "Triple-energy window (TEW)",
        "c": [
          "No scatter correction",
          "Triple-energy window (TEW)",
          "Single broad window",
          "CT-based only"
        ],
        "e": "TEW uses two narrow windows flanking the photopeak to estimate scatter contribution within the main window.",
        "d": 6
      },
      {
        "id": "nm28",
        "q": "Thyroid uptake probe measures?",
        "a": "% of I-131/I-123 uptake by thyroid",
        "c": [
          "Thyroid gland size via ultrasound",
          "% of I-131/I-123 uptake by thyroid",
          "Thyroid blood flow measurement",
          "Thyroid gland temperature reading"
        ],
        "e": "NaI(Tl) probe counts over thyroid vs standard to determine fractional uptake ‚Äî guides I-131 therapy dosing.",
        "d": 4
      },
      {
        "id": "nm29",
        "q": "PET ring diameter effect?",
        "a": "Larger ring = less sensitivity, fits larger patients",
        "c": [
          "No effect on imaging performance at all",
          "Larger ring = less sensitivity, fits larger patients",
          "Smaller ring is always clinically better",
          "Ring size only affects spatial resolution"
        ],
        "e": "Solid angle subtended by detectors decreases with larger rings (lower geometric efficiency), but larger bores accommodate bigger patients.",
        "d": 6
      },
      {
        "id": "nm30",
        "q": "CALC: I-131 treatment activity for thyroid ablation (typical)?",
        "a": "1110-3700 MBq (30-100 mCi)",
        "c": [
          "37 MBq (1 mCi)",
          "370 MBq (10 mCi)",
          "1110-3700 MBq (30-100 mCi)",
          "7400 MBq (200 mCi)"
        ],
        "e": "Ablation of thyroid remnants after surgery typically uses 1.1-3.7 GBq. Higher activities for metastatic disease.",
        "d": 5
      }
    ],
    "diag": [
      {
        "id": "dg01",
        "q": "Mammography anode material?",
        "a": "Molybdenum / Tungsten",
        "c": [
          "Copper",
          "Molybdenum / Tungsten",
          "Rhodium only",
          "Lead"
        ],
        "e": "Mo produces 17-20 keV characteristic X-rays optimal for breast contrast."
      },
      {
        "id": "dg02",
        "q": "CT dose metric for volume?",
        "a": "CTDIvol",
        "c": [
          "DAP",
          "CTDIvol",
          "DLP",
          "ESE"
        ],
        "e": "Average dose in a standard phantom for a single rotation. Measured in mGy."
      },
      {
        "id": "dg03",
        "q": "CT dose metric for exam length?",
        "a": "DLP",
        "c": [
          "CTDIvol",
          "DLP",
          "DAP",
          "Entrance dose"
        ],
        "e": "Dose-Length Product = CTDIvol √ó scan length (mGy¬∑cm)."
      },
      {
        "id": "dg04",
        "q": "Effective dose unit?",
        "a": "mSv",
        "c": [
          "mGy",
          "mSv",
          "mR",
          "MU"
        ],
        "e": "Uses tissue weighting factors to estimate stochastic risk from partial-body exposure."
      },
      {
        "id": "dg05",
        "q": "Fluoroscopy dose metric?",
        "a": "DAP (Dose Area Product)",
        "c": [
          "CTDIvol",
          "DAP (Dose Area Product)",
          "DLP",
          "ESE"
        ],
        "e": "DAP (Gy¬∑cm¬≤) captures both dose intensity and beam area."
      },
      {
        "id": "dg06",
        "q": "Typical chest X-ray effective dose?",
        "a": "~0.02 mSv",
        "c": [
          "~0.001 mSv",
          "~0.02 mSv",
          "~1 mSv",
          "~7 mSv"
        ],
        "e": "One of the lowest medical exposures. The reference unit for public communication."
      },
      {
        "id": "dg07",
        "q": "Typical CT abdomen effective dose?",
        "a": "~8-10 mSv",
        "c": [
          "~0.5 mSv",
          "~2 mSv",
          "~8-10 mSv",
          "~25 mSv"
        ],
        "e": "Equivalent to ~400-500 chest X-rays. Justification and optimisation essential."
      },
      {
        "id": "dg08",
        "q": "Hounsfield unit of water?",
        "a": "0 HU",
        "c": [
          "-1000 HU",
          "0 HU",
          "100 HU",
          "1000 HU"
        ],
        "e": "Water = 0 by definition. Air = -1000. Dense bone ~+1000."
      },
      {
        "id": "dg09",
        "q": "Hounsfield unit of air?",
        "a": "-1000 HU",
        "c": [
          "-1000 HU",
          "-500 HU",
          "0 HU",
          "-100 HU"
        ],
        "e": "HU = 1000 √ó (Œº_tissue - Œº_water) / Œº_water."
      },
      {
        "id": "dg10",
        "q": "Heel effect occurs in?",
        "a": "X-ray tube anode",
        "c": [
          "Collimator",
          "X-ray tube anode",
          "Image receptor",
          "Grid"
        ],
        "e": "X-rays from deeper in the anode are more attenuated ‚Üí intensity variation."
      },
      {
        "id": "dg11",
        "q": "AEC stands for?",
        "a": "Automatic Exposure Control",
        "c": [
          "Automatic Energy Control",
          "Automatic Exposure Control",
          "Automated Emission Check",
          "Anode Excitation Current"
        ],
        "e": "Terminates exposure when detector receives sufficient signal for diagnostic quality."
      },
      {
        "id": "dg12",
        "q": "kVp affects primarily?",
        "a": "Contrast & penetration",
        "c": [
          "Spatial resolution",
          "Contrast & penetration",
          "Focal spot size",
          "Detector efficiency"
        ],
        "e": "Higher kVp = more penetrating beam, lower contrast. Trade-off with patient dose."
      },
      {
        "id": "dg13",
        "q": "mAs affects primarily?",
        "a": "Quantity of radiation (dose)",
        "c": [
          "Beam energy",
          "Quantity of radiation (dose)",
          "Beam penetration",
          "Image contrast"
        ],
        "e": "Doubling mAs doubles dose and halves quantum noise."
      },
      {
        "id": "dg14",
        "q": "Digital detector types (name 2)?",
        "a": "CR (PSP) and DR (flat panel)",
        "c": [
          "Film and screen",
          "CR (PSP) and DR (flat panel)",
          "Image intensifier only",
          "CCD only"
        ],
        "e": "CR uses photostimulable phosphor plates; DR uses amorphous silicon or selenium flat panels."
      },
      {
        "id": "dg15",
        "q": "Nyquist frequency relates to?",
        "a": "Spatial resolution limit",
        "c": [
          "Dose efficiency",
          "Spatial resolution limit",
          "Contrast",
          "Noise"
        ],
        "e": "Maximum spatial frequency a detector can resolve = 1/(2 √ó pixel pitch)."
      },
      {
        "id": "dg16",
        "q": "DQE stands for?",
        "a": "Detective Quantum Efficiency",
        "c": [
          "Dose Quality Estimate",
          "Detective Quantum Efficiency",
          "Digital Quality Enhancement",
          "Detector Quench Effect"
        ],
        "e": "DQE measures how efficiently a detector converts incident X-ray quanta to useful signal. Higher DQE = better image quality per dose.",
        "d": 5
      },
      {
        "id": "dg17",
        "q": "CT reconstruction algorithm (standard)?",
        "a": "Filtered back projection (FBP)",
        "c": [
          "Simple back projection",
          "Filtered back projection (FBP)",
          "Maximum likelihood",
          "Direct Fourier"
        ],
        "e": "FBP applies a ramp filter before back-projecting to remove blurring. Iterative reconstruction is increasingly replacing FBP.",
        "d": 4
      },
      {
        "id": "dg18",
        "q": "Iterative reconstruction advantage?",
        "a": "Lower noise at same dose (dose saving)",
        "c": [
          "Faster computation and processing",
          "Lower noise at same dose (dose saving)",
          "Always better spatial resolution",
          "Simpler mathematical algorithm"
        ],
        "e": "Iterative methods model noise and physics more accurately, enabling 20-40% dose reduction while maintaining image quality.",
        "d": 5
      },
      {
        "id": "dg19",
        "q": "Beam hardening artefact cause?",
        "a": "Low-energy photon preferential absorption",
        "c": [
          "Patient involuntary motion blur",
          "Low-energy photon preferential absorption",
          "Detector element malfunction error",
          "Image reconstruction algorithm bug"
        ],
        "e": "Polychromatic beam loses low-energy photons passing through dense structures, shifting the mean energy upward and causing cupping/streak artefacts.",
        "d": 5
      },
      {
        "id": "dg20",
        "q": "CT number accuracy tolerance?",
        "a": "¬±4 HU for water",
        "c": [
          "¬±1 HU",
          "¬±4 HU for water",
          "¬±10 HU",
          "¬±20 HU"
        ],
        "e": "Water should read 0 ¬± 4 HU. Deviations indicate calibration issues affecting dose calculations when CT is used for RT planning.",
        "d": 5
      },
      {
        "id": "dg21",
        "q": "Anti-scatter grid purpose?",
        "a": "Reduce scatter radiation at detector",
        "c": [
          "Increase overall patient dose",
          "Reduce scatter radiation at detector",
          "Improve spatial resolution limit",
          "Filter out low-energy photons"
        ],
        "e": "Lead strips absorb scatter photons (typically moving at oblique angles) while transmitting primary photons, improving contrast.",
        "d": 3
      },
      {
        "id": "dg22",
        "q": "Grid ratio definition?",
        "a": "Height of lead strips / gap between strips",
        "c": [
          "Number of strips per cm",
          "Height of lead strips / gap between strips",
          "Grid frequency / strip width",
          "Lead content percentage"
        ],
        "e": "Higher grid ratios (e.g., 12:1) absorb more scatter but require higher exposure. Common values: 8:1 to 12:1.",
        "d": 5
      },
      {
        "id": "dg23",
        "q": "Mammography compressed breast thickness (typical)?",
        "a": "4-6 cm",
        "c": [
          "1-2 cm",
          "4-6 cm",
          "8-10 cm",
          "12-15 cm"
        ],
        "e": "Compression reduces breast thickness to 4-6 cm, improving contrast, reducing dose, and separating overlapping structures.",
        "d": 3
      },
      {
        "id": "dg24",
        "q": "Dual-energy CT application?",
        "a": "Material decomposition, virtual non-contrast",
        "c": [
          "Only faster scanning acquisition",
          "Material decomposition, virtual non-contrast",
          "Higher spatial resolution always",
          "Lower radiation dose guaranteed"
        ],
        "e": "Two energy datasets enable material characterisation (e.g., iodine mapping, uric acid detection) and virtual non-contrast images.",
        "d": 6
      },
      {
        "id": "dg25",
        "q": "MTF measures?",
        "a": "Resolution vs spatial frequency function",
        "c": [
          "Dose efficiency measurement metric",
          "Resolution vs spatial frequency function",
          "Contrast-to-noise ratio indicator",
          "Patient throughput rate metric"
        ],
        "e": "Modulation Transfer Function quantifies how well a system preserves contrast at different spatial frequencies. MTF=1 at zero frequency.",
        "d": 6
      },
      {
        "id": "dg26",
        "q": "Tube loading (heat units) depends on?",
        "a": "kVp √ó mA √ó time √ó rectification factor",
        "c": [
          "Peak kilovoltage setting only",
          "Tube current-time product only",
          "kVp √ó mA √ó time √ó rectification factor",
          "Focal spot size setting only"
        ],
        "e": "Heat generated in the anode limits continuous use. Rotating anodes dissipate heat more effectively than stationary.",
        "d": 5
      },
      {
        "id": "dg27",
        "q": "CALC: Patient effective dose from CT scan. DLP=600 mGy¬∑cm, k-factor=0.015 mSv/(mGy¬∑cm). Effective dose?",
        "a": "9 mSv",
        "c": [
          "6 mSv",
          "9 mSv",
          "12 mSv",
          "15 mSv"
        ],
        "e": "E = DLP √ó k = 600 √ó 0.015 = 9 mSv. k-factors are region-specific (abdomen ‚âà 0.015, head ‚âà 0.0021).",
        "d": 5
      },
      {
        "id": "dg28",
        "q": "Windowing in CT adjusts?",
        "a": "Display contrast & brightness (WW/WL)",
        "c": [
          "Actual radiation dose to patient",
          "Display contrast & brightness (WW/WL)",
          "Image spatial resolution setting",
          "CT scan protocol parameters"
        ],
        "e": "Window Width controls contrast range; Window Level (centre) controls brightness. Lung window: WW=1500, WL=-600. Bone: WW=2000, WL=300.",
        "d": 3
      },
      {
        "id": "dg29",
        "q": "Focal spot size affects?",
        "a": "Geometric unsharpness (resolution)",
        "c": [
          "Dose detection efficiency only",
          "Geometric unsharpness (resolution)",
          "Image contrast properties only",
          "Detector response sensitivity"
        ],
        "e": "Smaller focal spot = sharper image but lower tube loading capacity. Mammography uses 0.1-0.3 mm focal spots.",
        "d": 4
      },
      {
        "id": "dg30",
        "q": "Pitch in helical CT definition?",
        "a": "Table travel per rotation / collimation",
        "c": [
          "Peak voltage / current ratio value",
          "Table travel per rotation / collimation",
          "Slice thickness / pixel size ratio",
          "Rotation time / scan length ratio"
        ],
        "e": "Pitch > 1: gaps between rotations (faster, lower dose). Pitch < 1: overlapping data (slower, higher dose, better quality).",
        "d": 5
      }
    ],
    "radiobio": [
      {
        "id": "rb01",
        "q": "Linear-quadratic model formula?",
        "a": "S = e^(‚àíŒ±D ‚àí Œ≤D¬≤)",
        "c": [
          "S = e^(‚àíŒ±D)",
          "S = e^(‚àíŒ±D ‚àí Œ≤D¬≤)",
          "S = 1 ‚àí e^(‚àíD)",
          "S = Œ±D + Œ≤D¬≤"
        ],
        "e": "Œ± = single-hit kills (linear), Œ≤ = two-hit kills (quadratic). Foundation of fractionation theory."
      },
      {
        "id": "rb02",
        "q": "Œ±/Œ≤ ratio for late-responding tissue?",
        "a": "~3 Gy",
        "c": [
          "~1 Gy",
          "~3 Gy",
          "~10 Gy",
          "~20 Gy"
        ],
        "e": "Late tissues (spinal cord, lung) are more sensitive to fraction size ‚Äî the basis for conventional 2 Gy fractionation."
      },
      {
        "id": "rb03",
        "q": "Œ±/Œ≤ ratio for early-responding tissue?",
        "a": "~10 Gy",
        "c": [
          "~1 Gy",
          "~3 Gy",
          "~10 Gy",
          "~20 Gy"
        ],
        "e": "Fast-dividing tissues (tumours, skin, mucosa) are less sensitive to fraction size changes."
      },
      {
        "id": "rb04",
        "q": "4 R's of radiobiology?",
        "a": "Repair, Redistribution, Repopulation, Reoxygenation",
        "c": [
          "Repair, Redistribution, Repopulation, Reoxygenation",
          "Repair, Rejection, Regrowth, Recovery",
          "Resistance, Repair, Redistribution, Rejection",
          "Reoxygenation, Recovery, Resistance, Repair"
        ],
        "e": "The biological rationale for fractionation ‚Äî each R favours tumour kill over normal tissue damage."
      },
      {
        "id": "rb05",
        "q": "OER stands for?",
        "a": "Oxygen Enhancement Ratio",
        "c": [
          "Optical Emission Ratio",
          "Oxygen Enhancement Ratio",
          "Output Energy Ratio",
          "Organ Equivalence Ratio"
        ],
        "e": "Ratio of doses needed for same effect in hypoxic vs oxygenated cells."
      },
      {
        "id": "rb06",
        "q": "OER for photons is approximately?",
        "a": "2.5 - 3.0",
        "c": [
          "1.0",
          "1.5",
          "2.5 - 3.0",
          "5.0"
        ],
        "e": "Hypoxic cells need 2.5-3√ó more dose. Reoxygenation between fractions helps overcome this."
      },
      {
        "id": "rb07",
        "q": "RBE stands for?",
        "a": "Relative Biological Effectiveness",
        "c": [
          "Radiation Beam Energy",
          "Relative Biological Effectiveness",
          "Relative Beam Efficiency",
          "Radiobiological Effect"
        ],
        "e": "Compares biological effect of different radiation types relative to a reference (250 kVp X-rays)."
      },
      {
        "id": "rb08",
        "q": "RBE reference radiation?",
        "a": "250 kVp X-rays",
        "c": [
          "Co-60",
          "250 kVp X-rays",
          "Cs-137",
          "6 MV photons"
        ],
        "e": "Historical standard. RBE = Dose(reference) / Dose(test) for same biological effect."
      },
      {
        "id": "rb09",
        "q": "LET stands for?",
        "a": "Linear Energy Transfer",
        "c": [
          "Low Energy Threshold",
          "Linear Energy Transfer",
          "Lateral Emission Transfer",
          "Logarithmic Energy Transformation"
        ],
        "e": "Energy deposited per unit path length (keV/Œºm). Higher LET = more biological damage per track."
      },
      {
        "id": "rb10",
        "q": "High-LET radiation example?",
        "a": "Alpha particles",
        "c": [
          "X-rays",
          "Electrons",
          "Alpha particles",
          "Gamma rays"
        ],
        "e": "Alphas deposit ~100 keV/Œºm vs ~0.2 keV/Œºm for photons. Dense ionisation = more lethal."
      },
      {
        "id": "rb11",
        "q": "TCP stands for?",
        "a": "Tumour Control Probability",
        "c": [
          "Total Control Percentage",
          "Tumour Control Probability",
          "Treatment Completion Plan",
          "Tissue Complication Probability"
        ],
        "e": "Probability of eradicating all clonogenic tumour cells. Sigmoid function of dose."
      },
      {
        "id": "rb12",
        "q": "NTCP stands for?",
        "a": "Normal Tissue Complication Probability",
        "c": [
          "Normal Tissue Control Probability",
          "Normal Tissue Complication Probability",
          "Non-Target Complication Percentage",
          "Nominal Tissue Cure Probability"
        ],
        "e": "Probability of causing a specific complication. Also a sigmoid function of dose."
      },
      {
        "id": "rb13",
        "q": "Therapeutic ratio is?",
        "a": "TCP / NTCP",
        "c": [
          "Dose / Volume",
          "TCP / NTCP",
          "Œ± / Œ≤",
          "OER / RBE"
        ],
        "e": "Wider separation = better. RT aims to maximise TCP while keeping NTCP acceptably low."
      },
      {
        "id": "rb14",
        "q": "BED formula?",
        "a": "BED = nd(1 + d/(Œ±/Œ≤))",
        "c": [
          "BED = nD",
          "BED = nd(1 + d/(Œ±/Œ≤))",
          "BED = D √ó RBE",
          "BED = Œ±D + Œ≤D¬≤"
        ],
        "e": "Biologically Effective Dose. Allows comparison of different fractionation schedules."
      },
      {
        "id": "rb15",
        "q": "Prostate cancer Œ±/Œ≤?",
        "a": "~1.5 Gy (low)",
        "c": [
          "~1.5 Gy (low)",
          "~3 Gy",
          "~10 Gy",
          "~20 Gy"
        ],
        "e": "Unusually low ‚Äî prostate tumours behave like late-responding tissue. Supports hypofractionation."
      },
      {
        "id": "rb16",
        "q": "Cell cycle most radiosensitive phase?",
        "a": "M and late G2",
        "c": [
          "G1",
          "S phase",
          "M and late G2",
          "G0"
        ],
        "e": "Mitosis and late G2 have condensed chromosomes and reduced repair capacity ‚Äî most vulnerable to radiation damage.",
        "d": 4
      },
      {
        "id": "rb17",
        "q": "Cell cycle most radioresistant phase?",
        "a": "Late S phase",
        "c": [
          "G1",
          "Late S phase",
          "M phase",
          "G2"
        ],
        "e": "Late S phase has active homologous recombination repair and sister chromatids available as templates.",
        "d": 5
      },
      {
        "id": "rb18",
        "q": "Oxygen fixation hypothesis?",
        "a": "O‚ÇÇ makes DNA damage permanent (fixes radicals)",
        "c": [
          "O‚ÇÇ prevents all radiation DNA damage",
          "O‚ÇÇ makes DNA damage permanent (fixes radicals)",
          "O‚ÇÇ actively repairs damaged DNA strands",
          "O‚ÇÇ completely blocks radiation effects"
        ],
        "e": "Oxygen reacts with radiation-produced free radicals on DNA, making the damage irreparable. Without O‚ÇÇ, the radical can be chemically restored.",
        "d": 5
      },
      {
        "id": "rb19",
        "q": "Accelerated repopulation begins at (H&N)?",
        "a": "~4 weeks into treatment",
        "c": [
          "Day 1",
          "~2 weeks",
          "~4 weeks into treatment",
          "~6 weeks"
        ],
        "e": "After ~28 days, surviving tumour clonogens proliferate faster. This is why treatment breaks and prolongation are detrimental.",
        "d": 6
      },
      {
        "id": "rb20",
        "q": "EQD2 formula?",
        "a": "EQD2 = D(d+Œ±/Œ≤)/(2+Œ±/Œ≤)",
        "c": [
          "EQD2 = total dose D √ó d / 2",
          "EQD2 = D(d+Œ±/Œ≤)/(2+Œ±/Œ≤)",
          "EQD2 = BED √ó Œ±/Œ≤ ratio",
          "EQD2 = D / (1 + d/Œ±Œ≤)"
        ],
        "e": "Equivalent Dose in 2 Gy fractions. Converts any schedule to its equivalent in standard 2 Gy fractions for comparison.",
        "d": 6
      },
      {
        "id": "rb21",
        "q": "CALC: BED for 50 Gy in 5 fx, Œ±/Œ≤ = 10 Gy?",
        "a": "100 Gy‚ÇÅ‚ÇÄ",
        "c": [
          "80 Gy‚ÇÅ‚ÇÄ",
          "100 Gy‚ÇÅ‚ÇÄ",
          "120 Gy‚ÇÅ‚ÇÄ",
          "150 Gy‚ÇÅ‚ÇÄ"
        ],
        "e": "d = 50/5 = 10 Gy per fraction. BED = nd(1 + d/(Œ±/Œ≤)) = 50 √ó (1 + 10/10) = 50 √ó 2 = 100 Gy‚ÇÅ‚ÇÄ.",
        "d": 6
      },
      {
        "id": "rb22",
        "q": "Sublethal damage repair half-time?",
        "a": "~1-2 hours",
        "c": [
          "~5 minutes",
          "~1-2 hours",
          "~6 hours",
          "~24 hours"
        ],
        "e": "Most sublethal damage is repaired within 1-2 hours. This is why fractions are spaced ‚â•6 hours apart (‚â•3 half-times).",
        "d": 5
      },
      {
        "id": "rb23",
        "q": "Bystander effect?",
        "a": "Unirradiated cells near irradiated cells show damage",
        "c": [
          "All cells receive equal dose",
          "Unirradiated cells near irradiated cells show damage",
          "Only directly hit cells are affected",
          "Radiation has no indirect effects"
        ],
        "e": "Irradiated cells release signalling molecules that can induce DNA damage, apoptosis, or genomic instability in neighbouring unirradiated cells.",
        "d": 6
      },
      {
        "id": "rb24",
        "q": "Abscopal effect?",
        "a": "Distant unirradiated tumour regression",
        "c": [
          "Local tumour volume shrinkage",
          "Distant unirradiated tumour regression",
          "Increased tumour growth rate",
          "Adjacent normal organ damage"
        ],
        "e": "Rare phenomenon where localised radiation triggers immune response causing regression of metastases outside the treatment field.",
        "d": 6
      },
      {
        "id": "rb25",
        "q": "DSB stands for?",
        "a": "Double Strand Break",
        "c": [
          "Dose-Surface Barrier",
          "Double Strand Break",
          "Distal Scatter Boundary",
          "Direct Signal Beam"
        ],
        "e": "DSBs are the most lethal form of DNA damage. A single unrepaired DSB can kill a cell. Repaired by NHEJ or HR.",
        "d": 3
      },
      {
        "id": "rb26",
        "q": "NHEJ repair mechanism?",
        "a": "Non-Homologous End Joining (error-prone)",
        "c": [
          "Normal Homologous End Junction",
          "Non-Homologous End Joining (error-prone)",
          "Nuclear Hydrogen Exchange Junction",
          "Nucleotide Hybridisation End Joining"
        ],
        "e": "NHEJ directly ligates broken DNA ends without a template ‚Äî fast but error-prone. Dominant repair pathway in mammalian cells.",
        "d": 5
      },
      {
        "id": "rb27",
        "q": "Tumour hypoxia effect on RT?",
        "a": "Increases radioresistance",
        "c": [
          "Increases radiosensitivity",
          "Increases radioresistance",
          "No effect on response",
          "Improves local control"
        ],
        "e": "Hypoxic tumour cells require 2.5-3√ó higher dose for equivalent kill. Strategies: fractionation (reoxygenation), hypoxic sensitisers, carbogen breathing.",
        "d": 4
      },
      {
        "id": "rb28",
        "q": "CALC: EQD2 for 30 Gy / 10 fx, Œ±/Œ≤ = 3 Gy?",
        "a": "36 Gy",
        "c": [
          "30 Gy",
          "36 Gy",
          "42 Gy",
          "50 Gy"
        ],
        "e": "d = 3 Gy per fraction. EQD2 = D √ó (d + Œ±/Œ≤)/(2 + Œ±/Œ≤) = 30 √ó (3+3)/(2+3) = 30 √ó 6/5 = 36 Gy.",
        "d": 7
      },
      {
        "id": "rb29",
        "q": "Radiosensitiser example?",
        "a": "Cisplatin (concurrent chemoRT)",
        "c": [
          "Amifostine",
          "Cisplatin (concurrent chemoRT)",
          "Vitamin C",
          "Lead shielding"
        ],
        "e": "Cisplatin inhibits DNA repair and synergises with radiation. Standard for H&N, cervix, lung chemoradiation.",
        "d": 4
      },
      {
        "id": "rb30",
        "q": "Radioprotector example?",
        "a": "Amifostine (radical scavenger)",
        "c": [
          "Cisplatin (DNA crosslinker)",
          "Amifostine (radical scavenger)",
          "5-FU (antimetabolite drug)",
          "Carboplatin (alkylating agent)"
        ],
        "e": "Amifostine (WR-2721) is a thiol compound that scavenges free radicals, selectively protecting normal tissues over tumours.",
        "d": 5
      }
    ],
    "radprot": [
      {
        "id": "rp01",
        "q": "ALARA stands for?",
        "a": "As Low As Reasonably Achievable",
        "c": [
          "As Low As Readily Available",
          "As Low As Reasonably Achievable",
          "All Levels Are Routinely Assessed",
          "Acute Limits And Radiation Assessments"
        ],
        "e": "The overarching principle: minimise dose consistent with practical constraints."
      },
      {
        "id": "rp02",
        "q": "Three principles of radiation protection?",
        "a": "Time, Distance, Shielding",
        "c": [
          "Time, Distance, Shielding",
          "kVp, mAs, Filtration",
          "Dose, Volume, Fractionation",
          "Energy, Fluence, Exposure"
        ],
        "e": "Minimise time, maximise distance (inverse square), interpose shielding."
      },
      {
        "id": "rp03",
        "q": "Inverse square law: double distance ‚Üí",
        "a": "¬º dose",
        "c": [
          "¬Ω dose",
          "¬º dose",
          "‚Öõ dose",
          "Same dose"
        ],
        "e": "Dose ‚àù 1/r¬≤. Double the distance = quarter the dose. The most powerful protection tool."
      },
      {
        "id": "rp04",
        "q": "Primary barrier shielding material?",
        "a": "Concrete or lead",
        "c": [
          "Wood",
          "Concrete or lead",
          "Glass",
          "Aluminium only"
        ],
        "e": "High-Z materials attenuate MV beams. Concrete is most common; lead for space-constrained areas."
      },
      {
        "id": "rp05",
        "q": "HVL stands for?",
        "a": "Half-Value Layer",
        "c": [
          "High-Voltage Limit",
          "Half-Value Layer",
          "Hazard Verification Level",
          "Heavy Voltage Load"
        ],
        "e": "Thickness of material to reduce beam intensity by 50%. Depends on energy and material."
      },
      {
        "id": "rp06",
        "q": "TVL stands for?",
        "a": "Tenth-Value Layer",
        "c": [
          "Total Value Layer",
          "Tenth-Value Layer",
          "Transmission Verification Level",
          "Tissue Volume Layer"
        ],
        "e": "Reduces beam to 10%. TVL ‚âà 3.32 √ó HVL."
      },
      {
        "id": "rp07",
        "q": "TVL reduces beam to?",
        "a": "10% (factor of 10)",
        "c": [
          "50%",
          "10% (factor of 10)",
          "1%",
          "0.1%"
        ],
        "e": "One TVL = factor of 10 reduction. Two TVLs = factor of 100, etc."
      },
      {
        "id": "rp08",
        "q": "Shielding design report?",
        "a": "NCRP 151",
        "c": [
          "NCRP 49",
          "NCRP 116",
          "NCRP 147",
          "NCRP 151"
        ],
        "e": "NCRP 151 covers structural shielding design for megavoltage RT facilities."
      },
      {
        "id": "rp09",
        "q": "Workload (W) unit?",
        "a": "Gy/week at 1 m",
        "c": [
          "mSv/year",
          "Gy/week at 1 m",
          "MU/hour",
          "R/min"
        ],
        "e": "Total dose output at 1 m from source per week. Key input for shielding calculations."
      },
      {
        "id": "rp10",
        "q": "Use factor (U) for primary wall?",
        "a": "¬º (typical)",
        "c": [
          "1",
          "¬Ω",
          "¬º (typical)",
          "1/16"
        ],
        "e": "Fraction of time beam is directed at that wall. ¬º assumes 4 cardinal gantry angles."
      },
      {
        "id": "rp11",
        "q": "Occupancy factor (T) for office next door?",
        "a": "1 (full occupancy)",
        "c": [
          "1 (full occupancy)",
          "¬Ω",
          "¬º",
          "1/16"
        ],
        "e": "T=1 for areas with permanent occupants. Lower for corridors (¬º), toilets (1/16)."
      },
      {
        "id": "rp12",
        "q": "Neutron contamination risk starts at?",
        "a": "> 10 MV photons",
        "c": [
          "> 4 MV",
          "> 6 MV",
          "> 10 MV photons",
          "> 18 MeV electrons"
        ],
        "e": "Photonuclear threshold ~8-10 MV. Requires additional shielding (polyethylene, borated materials)."
      },
      {
        "id": "rp13",
        "q": "Area monitor for linac room?",
        "a": "Ion chamber survey meter",
        "c": [
          "Geiger-M√ºller only",
          "Ion chamber survey meter",
          "Film badge",
          "TLD ring"
        ],
        "e": "IC survey meters give accurate dose rate readings across the energy range."
      },
      {
        "id": "rp14",
        "q": "Personal dosimeter types (name 2)?",
        "a": "TLD and OSL",
        "c": [
          "Film and screen",
          "TLD and OSL",
          "Ion chamber only",
          "Scintillator pair"
        ],
        "e": "TLD (thermoluminescence) and OSL (optically stimulated luminescence) are standard personal monitors."
      },
      {
        "id": "rp15",
        "q": "Maze in bunker design reduces?",
        "a": "Scattered/leakage at door",
        "c": [
          "Primary beam only",
          "Scattered/leakage at door",
          "Noise",
          "Ozone"
        ],
        "e": "Multiple scattering events along the maze attenuate dose to manageable levels at the entrance."
      },
      {
        "id": "rp16",
        "q": "Secondary barrier attenuates?",
        "a": "Scatter and leakage radiation",
        "c": [
          "Primary beam only",
          "Scatter and leakage radiation",
          "Neutrons only",
          "Patient scatter only"
        ],
        "e": "Secondary barriers are thinner than primary because they shield against lower-energy scatter and head leakage (~0.1% of primary).",
        "d": 4
      },
      {
        "id": "rp17",
        "q": "Head leakage limit (linac)?",
        "a": "‚â§ 0.1% of useful beam at 1 m",
        "c": [
          "‚â§ 0.01%",
          "‚â§ 0.1% of useful beam at 1 m",
          "‚â§ 1%",
          "‚â§ 5%"
        ],
        "e": "IEC standard: leakage radiation at 1 m from source must not exceed 0.1% of the maximum dose rate of the useful beam.",
        "d": 5
      },
      {
        "id": "rp18",
        "q": "Effective dose calculation uses?",
        "a": "Tissue weighting factors (w_T)",
        "c": [
          "Absorbed dose only",
          "Tissue weighting factors (w_T)",
          "Radiation weighting only",
          "Distance from source"
        ],
        "e": "E = Œ£ w_T √ó H_T. Tissue weighting factors sum to 1.0 and reflect relative radiation sensitivity of different organs.",
        "d": 4
      },
      {
        "id": "rp19",
        "q": "Equivalent dose calculation uses?",
        "a": "Radiation weighting factor (w_R)",
        "c": [
          "Tissue weighting factor",
          "Radiation weighting factor (w_R)",
          "Quality factor only",
          "Dose rate factor"
        ],
        "e": "H_T = Œ£ w_R √ó D_T,R. w_R = 1 for photons/electrons, 20 for alpha particles, 2.5-21 for neutrons (energy-dependent).",
        "d": 5
      },
      {
        "id": "rp20",
        "q": "w_R for photons and electrons?",
        "a": "1",
        "c": [
          "1",
          "5",
          "10",
          "20"
        ],
        "e": "Low-LET radiations (photons, electrons) have w_R = 1. The absorbed dose in Gy equals equivalent dose in Sv.",
        "d": 3
      },
      {
        "id": "rp21",
        "q": "w_R for alpha particles?",
        "a": "20",
        "c": [
          "1",
          "5",
          "10",
          "20"
        ],
        "e": "High-LET alpha particles cause dense ionisation tracks ‚Äî 20√ó more biologically damaging per unit dose than photons.",
        "d": 4
      },
      {
        "id": "rp22",
        "q": "Radiation area monitoring: passive vs active?",
        "a": "Passive: TLD/film; Active: ion chamber/GM",
        "c": [
          "Both use ion chambers",
          "Passive: TLD/film; Active: ion chamber/GM",
          "Passive gives real-time readings",
          "Active uses TLD badges"
        ],
        "e": "Passive dosimeters integrate dose over time. Active monitors give real-time readings with alarms for dose rate thresholds.",
        "d": 4
      },
      {
        "id": "rp23",
        "q": "Controlled area signage requirement?",
        "a": "Trefoil symbol + access restrictions",
        "c": [
          "No special signage is needed",
          "Trefoil symbol + access restrictions",
          "Simple 'No Entry' sign only",
          "Red flashing warning light only"
        ],
        "e": "International radiation trefoil symbol, radiation type, dose rate information, and controlled access measures are required.",
        "d": 3
      },
      {
        "id": "rp24",
        "q": "Emergency procedure for stuck source (brachy)?",
        "a": "Evacuate, shield, call physics/RPO",
        "c": [
          "Wait for source to decay",
          "Evacuate, shield, call physics/RPO",
          "Pull applicator out immediately",
          "Turn off room lights"
        ],
        "e": "Stuck HDR source: evacuate patient area, maximise distance, use emergency container if available, contact physicist and RPO immediately.",
        "d": 5
      },
      {
        "id": "rp25",
        "q": "CALC: Annual dose to office (100% occupancy). Dose rate at wall = 0.5 ¬µSv/hr. Hours/year = 2000. Annual dose?",
        "a": "1.0 mSv",
        "c": [
          "0.5 mSv",
          "1.0 mSv",
          "2.0 mSv",
          "5.0 mSv"
        ],
        "e": "D = 0.5 ¬µSv/hr √ó 2000 hr = 1000 ¬µSv = 1.0 mSv. At the public limit ‚Äî shielding is just adequate.",
        "d": 5
      },
      {
        "id": "rp26",
        "q": "Neutron shielding material?",
        "a": "Polyethylene / borated polyethylene",
        "c": [
          "Lead shielding material only",
          "Polyethylene / borated polyethylene",
          "Steel plate shielding only",
          "Aluminium sheet shielding"
        ],
        "e": "Hydrogen-rich materials (poly) thermalise fast neutrons. Boron-10 then captures thermal neutrons via ¬π‚Å∞B(n,Œ±)‚Å∑Li reaction.",
        "d": 5
      },
      {
        "id": "rp27",
        "q": "Ozone production concern in linac bunkers?",
        "a": "Ventilation must clear O‚ÇÉ between treatments",
        "c": [
          "O‚ÇÉ is not produced by linacs",
          "Ventilation must clear O‚ÇÉ between treatments",
          "O‚ÇÉ is beneficial for patients",
          "Only at energies > 18 MV"
        ],
        "e": "UV and ionising radiation produces ozone (O‚ÇÉ) from air. NCRP 151 recommends ventilation providing 6-10 air changes per hour.",
        "d": 5
      },
      {
        "id": "rp28",
        "q": "CALC: Need to reduce 50 mSv/hr to 0.05 mSv/hr. Transmission = ?",
        "a": "0.001 (10‚Åª¬≥)",
        "c": [
          "0.01 (10‚Åª¬≤)",
          "0.001 (10‚Åª¬≥)",
          "0.0001 (10‚Åª‚Å¥)",
          "0.1 (10‚Åª¬π)"
        ],
        "e": "T = 0.05/50 = 0.001 = 10‚Åª¬≥. Need 3 TVLs of shielding. TVL‚ÇÅ may differ from TVL_eq for the material.",
        "d": 5
      },
      {
        "id": "rp29",
        "q": "Direct-shielded door vs maze design?",
        "a": "Direct-shielded door is heavier but saves space",
        "c": [
          "Maze is always preferred",
          "Direct-shielded door is heavier but saves space",
          "Direct door is always cheaper",
          "They provide equal protection"
        ],
        "e": "Mazeless designs use massive shielded doors (several tonnes) ‚Äî saves floor space but requires motorised door systems.",
        "d": 5
      },
      {
        "id": "rp30",
        "q": "Instantaneous dose rate (IDR) interlock?",
        "a": "Terminates beam if area dose rate exceeded",
        "c": [
          "Monitors patient dose only",
          "Terminates beam if area dose rate exceeded",
          "Controls beam energy",
          "Measures cumulative dose"
        ],
        "e": "Area radiation monitors with IDR interlocks automatically stop beam delivery if dose rate outside the bunker exceeds preset thresholds.",
        "d": 4
      }
    ],
    "regs": [
      {
        "id": "rg01",
        "q": "Occupational dose/yr (SA)?",
        "a": "20 mSv",
        "c": [
          "5 mSv",
          "10 mSv",
          "20 mSv",
          "50 mSv"
        ],
        "e": "ICRP/SA limit. Max 50 in any single year, 100 over 5 consecutive years."
      },
      {
        "id": "rg02",
        "q": "Controlled area limit?",
        "a": "‚â§ 5 mSv/yr",
        "c": [
          "‚â§ 1 mSv/yr",
          "‚â§ 5 mSv/yr",
          "‚â§ 20 mSv/yr",
          "‚â§ 50 mSv/yr"
        ],
        "e": "Areas requiring access control and monitoring for radiation workers."
      },
      {
        "id": "rg03",
        "q": "Uncontrolled area limit?",
        "a": "‚â§ 1 mSv/yr",
        "c": [
          "‚â§ 0.5 mSv/yr",
          "‚â§ 1 mSv/yr",
          "‚â§ 5 mSv/yr",
          "‚â§ 20 mSv/yr"
        ],
        "e": "Public areas ‚Äî corridors, waiting rooms, offices. Same as public dose limit."
      },
      {
        "id": "rg04",
        "q": "SASQART published by?",
        "a": "SAMPS/SAAPMB",
        "c": [
          "SAHPRA",
          "HPCSA",
          "SAMPS/SAAPMB",
          "IAEA"
        ],
        "e": "South African Standards for Quality Assurance in Radiotherapy ‚Äî the national QA guideline."
      },
      {
        "id": "rg05",
        "q": "SA radiation legislation?",
        "a": "Hazardous Substances Act (1973)",
        "c": [
          "National Health Act (2003)",
          "Hazardous Substances Act (1973)",
          "Medicines and Related Act",
          "Nuclear Energy Act (1999)"
        ],
        "e": "Act 15 of 1973, Group IV hazardous substances. Governs all non-nuclear radiation use."
      },
      {
        "id": "rg06",
        "q": "Pregnant worker limit?",
        "a": "2 mSv lower abdomen",
        "c": [
          "1 mSv total",
          "2 mSv lower abdomen",
          "5 mSv total",
          "0.5 mSv/month"
        ],
        "e": "For remainder of pregnancy once declared. Protects the embryo/fetus."
      },
      {
        "id": "rg07",
        "q": "SSDL stands for?",
        "a": "Secondary Standard Dosimetry Lab",
        "c": [
          "Safety Standard Dose Level",
          "Secondary Standard Dosimetry Lab",
          "SA Standard Dose Limit",
          "Stereotactic Standard Lab"
        ],
        "e": "Provides traceable calibrations for clinical dosimeters in SA."
      },
      {
        "id": "rg08",
        "q": "Professional registration body?",
        "a": "HPCSA",
        "c": [
          "SAHPRA",
          "HPCSA",
          "SAMPS",
          "SAAPMB"
        ],
        "e": "Health Professions Council of SA ‚Äî registers medical physicists and other health professionals."
      },
      {
        "id": "rg09",
        "q": "Equipment licensing body?",
        "a": "SAHPRA",
        "c": [
          "SAHPRA",
          "HPCSA",
          "SAMPS",
          "DoH"
        ],
        "e": "SA Health Products Regulatory Authority ‚Äî licenses all radiation-emitting equipment."
      },
      {
        "id": "rg10",
        "q": "5-year cumulative dose limit?",
        "a": "100 mSv",
        "c": [
          "50 mSv",
          "100 mSv",
          "150 mSv",
          "200 mSv"
        ],
        "e": "Ensures average ‚â§ 20 mSv/yr even if single years exceed it."
      },
      {
        "id": "rg11",
        "q": "Max dose in any single year?",
        "a": "50 mSv",
        "c": [
          "20 mSv",
          "30 mSv",
          "50 mSv",
          "100 mSv"
        ],
        "e": "Flexibility clause: up to 50 mSv in one year if 5-year average stays ‚â§ 20 mSv."
      },
      {
        "id": "rg12",
        "q": "Public annual dose limit?",
        "a": "1 mSv",
        "c": [
          "0.5 mSv",
          "1 mSv",
          "5 mSv",
          "20 mSv"
        ],
        "e": "ICRP recommended and adopted in SA. Excludes medical and natural background."
      },
      {
        "id": "rg67",
        "q": "HPCSA registration category for medical physicists?",
        "a": "Medical Physicist (diag/therapeutic)",
        "c": [
          "Radiographer registration category",
          "Medical Physicist (diag/therapeutic)",
          "Clinical Technologist category",
          "Radiation Therapist category"
        ],
        "e": "HPCSA registers medical physicists under the Professional Board for Radiography and Clinical Technology, with subspecialties in diagnostic or therapeutic physics.",
        "d": 3
      },
      {
        "id": "rg68",
        "q": "CEU points required per HPCSA cycle?",
        "a": "30 CEUs per cycle",
        "c": [
          "15 CEUs per cycle",
          "30 CEUs per cycle",
          "60 CEUs per cycle",
          "45 CEUs per cycle"
        ],
        "e": "HPCSA requires 30 Continuing Education Units per cycle for medical physicists. At least 5 must be in ethics, human rights, or medical law.",
        "d": 4
      },
      {
        "id": "rg69",
        "q": "HPCSA CEU cycle length?",
        "a": "12 months",
        "c": [
          "6 months",
          "12 months",
          "24 months",
          "36 months"
        ],
        "e": "The HPCSA CPD cycle runs for 12 months. Practitioners must accumulate the required CEUs within each annual cycle.",
        "d": 3
      },
      {
        "id": "rg70",
        "q": "Minimum ethics CEUs per HPCSA cycle?",
        "a": "5 CEUs in ethics",
        "c": [
          "2 CEUs in ethics",
          "5 CEUs in ethics",
          "10 CEUs in ethics",
          "No ethics minimum"
        ],
        "e": "HPCSA mandates at least 5 CEUs in ethics, human rights, or medical law per cycle to maintain registration.",
        "d": 5
      },
      {
        "id": "rg71",
        "q": "SAHPRA replaced which body?",
        "a": "Medicines Control Council (MCC)",
        "c": [
          "HPCSA regulatory arm",
          "Medicines Control Council (MCC)",
          "National Health Laboratory Service",
          "Medical Research Council"
        ],
        "e": "SAHPRA (South African Health Products Regulatory Authority) replaced the MCC in 2018, taking over regulation of medicines, medical devices, and radiation-emitting equipment.",
        "d": 3
      },
      {
        "id": "rg72",
        "q": "SAHPRA regulates radiation equipment under which Act?",
        "a": "Hazardous Substances Act (Act 15 of 1973)",
        "c": [
          "National Health Act (Act 61 of 2003)",
          "Hazardous Substances Act (Act 15 of 1973)",
          "Nuclear Energy Act (Act 46 of 1999)",
          "Medicines and Related Substances Act"
        ],
        "e": "SAHPRA regulates Group III and IV hazardous substances under the Hazardous Substances Act. Group IV covers radioactive materials and radiation-generating equipment.",
        "d": 5
      },
      {
        "id": "rg73",
        "q": "Group IV hazardous substances include?",
        "a": "Radioactive materials and X-ray equipment",
        "c": [
          "Flammable chemicals and solvents",
          "Radioactive materials and X-ray equipment",
          "Biological waste and pathogens",
          "Pharmaceutical drugs and medicines"
        ],
        "e": "Group IV of the Hazardous Substances Act specifically covers radioactive materials, radiation-generating equipment, and electronic products emitting radiation.",
        "d": 4
      },
      {
        "id": "rg74",
        "q": "NNR regulates which facilities?",
        "a": "Nuclear installations and vessels",
        "c": [
          "All hospitals with X-ray units",
          "Nuclear installations and vessels",
          "Medical device manufacturers",
          "All radiation therapy centres"
        ],
        "e": "The National Nuclear Regulator (NNR) regulates nuclear installations (reactors, enrichment plants) and nuclear vessels under the National Nuclear Regulator Act (Act 47 of 1999).",
        "d": 5
      },
      {
        "id": "rg75",
        "q": "Who issues a licence for a new linac installation?",
        "a": "SAHPRA (Radiation Control)",
        "c": [
          "HPCSA registration board",
          "SAHPRA (Radiation Control)",
          "National Nuclear Regulator",
          "Provincial Health Department"
        ],
        "e": "SAHPRA's Radiation Control Directorate issues licences for radiation-emitting equipment including linacs, under the Hazardous Substances Act.",
        "d": 4
      },
      {
        "id": "rg76",
        "q": "ICRP 103 tissue weighting factor for gonads?",
        "a": "0.08",
        "c": [
          "0.20",
          "0.12",
          "0.08",
          "0.05"
        ],
        "e": "ICRP 103 reduced the gonad weighting factor from 0.20 (ICRP 60) to 0.08, reflecting updated evidence on hereditary risk.",
        "d": 6
      },
      {
        "id": "rg77",
        "q": "ICRP 103 tissue weighting factor for breast?",
        "a": "0.12",
        "c": [
          "0.05",
          "0.08",
          "0.12",
          "0.20"
        ],
        "e": "ICRP 103 increased breast weighting from 0.05 to 0.12, recognising higher radiation-induced cancer risk in breast tissue.",
        "d": 6
      },
      {
        "id": "rg78",
        "q": "CALC: Worker receives 15 mSv in year 1 and 18 mSv in year 2. Max allowed in year 3 to stay within 5-year limit?",
        "a": "50 mSv",
        "c": [
          "17 mSv",
          "50 mSv",
          "67 mSv",
          "32 mSv"
        ],
        "e": "The 5-year limit is 100 mSv, and the single-year cap is 50 mSv. After 33 mSv in 2 years, 67 mSv remains over 3 years, but the annual cap of 50 mSv applies.",
        "d": 7
      },
      {
        "id": "rg79",
        "q": "CALC: How many TVLs to reduce dose rate from 40 mSv/hr to 0.04 mSv/hr?",
        "a": "3 TVLs",
        "c": [
          "2 TVLs",
          "3 TVLs",
          "4 TVLs",
          "5 TVLs"
        ],
        "e": "40 / 0.04 = 1000 = 10¬≥, so 3 TVLs are needed. Each TVL reduces intensity by a factor of 10.",
        "d": 5
      },
      {
        "id": "rg80",
        "q": "CALC: Source at 1 m gives 8 mSv/hr. Dose rate at 4 m?",
        "a": "0.5 mSv/hr",
        "c": [
          "2.0 mSv/hr",
          "1.0 mSv/hr",
          "0.5 mSv/hr",
          "0.25 mSv/hr"
        ],
        "e": "Inverse square law: 8 √ó (1/4)¬≤ = 8 √ó 1/16 = 0.5 mSv/hr. Distance is the most effective protection tool.",
        "d": 4
      },
      {
        "id": "rg81",
        "q": "ICRP 103 annual eye lens dose limit for workers?",
        "a": "20 mSv",
        "c": [
          "15 mSv",
          "20 mSv",
          "50 mSv",
          "150 mSv"
        ],
        "e": "ICRP revised the lens limit from 150 mSv to 20 mSv/year (averaged over 5 years, max 50 in a single year) based on cataract data.",
        "d": 6
      },
      {
        "id": "rg82",
        "q": "Annual extremity dose limit for workers?",
        "a": "500 mSv",
        "c": [
          "150 mSv",
          "250 mSv",
          "500 mSv",
          "1000 mSv"
        ],
        "e": "Hands, feet, and skin of extremities have a higher limit of 500 mSv/year because of their lower radiation sensitivity.",
        "d": 5
      },
      {
        "id": "rg83",
        "q": "Radiation Protection Officer (RPO) must be appointed when?",
        "a": "At every licensed radiation facility",
        "c": [
          "Only at nuclear installations",
          "At every licensed radiation facility",
          "Only when dose exceeds 5 mSv/yr",
          "Only at facilities with sealed sources"
        ],
        "e": "SA regulations require every facility holding a radiation licence to appoint a qualified RPO responsible for the radiation protection programme.",
        "d": 4
      },
      {
        "id": "rg84",
        "q": "Key RPO responsibility?",
        "a": "Ensure compliance with licence conditions",
        "c": [
          "Prescribe radiation treatment doses",
          "Ensure compliance with licence conditions",
          "Manufacture radiation equipment",
          "Issue HPCSA registrations"
        ],
        "e": "The RPO oversees personal dosimetry, area monitoring, waste management, incident reporting, and ensures all licence conditions are met.",
        "d": 3
      },
      {
        "id": "rg85",
        "q": "Personal dosimetry monitoring frequency in SA?",
        "a": "Monthly (routine)",
        "c": [
          "Weekly readout",
          "Monthly (routine)",
          "Quarterly readout",
          "Annual readout only"
        ],
        "e": "Personal dosimeters (TLD/OSL) are exchanged and read monthly in SA. This allows timely detection of elevated exposures.",
        "d": 4
      },
      {
        "id": "rg86",
        "q": "Investigation level for personal dosimetry in SA?",
        "a": "Above 1 mSv per month",
        "c": [
          "Above 0.1 mSv per month",
          "Above 1 mSv per month",
          "Above 5 mSv per month",
          "Above 20 mSv per month"
        ],
        "e": "Doses exceeding approximately 1 mSv per monitoring period trigger an investigation to identify causes and implement corrective actions.",
        "d": 6
      },
      {
        "id": "rg87",
        "q": "CALC: Pregnant worker declared at 8 weeks. Remaining pregnancy ~32 weeks. Max dose rate to abdomen?",
        "a": "0.0625 mSv/week",
        "c": [
          "0.125 mSv/week",
          "0.0625 mSv/week",
          "0.25 mSv/week",
          "0.50 mSv/week"
        ],
        "e": "Limit is 2 mSv to lower abdomen for remainder of pregnancy. 2 mSv / 32 weeks = 0.0625 mSv/week.",
        "d": 7
      },
      {
        "id": "rg88",
        "q": "IAEA BSS document number?",
        "a": "GSR Part 3",
        "c": [
          "Safety Series 115",
          "GSR Part 3",
          "GS-R-2",
          "SSR-6"
        ],
        "e": "The IAEA General Safety Requirements Part 3 (GSR Part 3, 2014) replaced Safety Series 115 as the international Basic Safety Standards for radiation protection.",
        "d": 6
      },
      {
        "id": "rg89",
        "q": "ICRP 105 covers?",
        "a": "Radiation protection in medicine",
        "c": [
          "Occupational dose limits",
          "Radiation protection in medicine",
          "Environmental monitoring",
          "Transport of radioactive materials"
        ],
        "e": "ICRP Publication 105 provides guidance on radiation protection specific to medical exposures, including justification and optimisation for patients.",
        "d": 5
      },
      {
        "id": "rg90",
        "q": "Three principles of ICRP radiation protection system?",
        "a": "Justification, optimisation, dose limitation",
        "c": [
          "Time, distance, shielding",
          "Justification, optimisation, dose limitation",
          "Detection, prevention, mitigation",
          "Monitoring, recording, reporting"
        ],
        "e": "ICRP 103 establishes justification (net benefit), optimisation (ALARA), and dose limitation (for workers/public, not patients) as the three pillars.",
        "d": 3
      },
      {
        "id": "rg91",
        "q": "Dose limits apply to which exposure category?",
        "a": "Occupational and public, not medical",
        "c": [
          "Medical exposures only",
          "Occupational and public, not medical",
          "All exposure categories equally",
          "Only occupational exposures"
        ],
        "e": "ICRP dose limits apply to planned occupational and public exposures. Medical patient exposures are governed by justification and optimisation, not dose limits.",
        "d": 5
      },
      {
        "id": "rg92",
        "q": "CALC: Shielding reduces dose rate from 200 mSv/hr to 0.2 mSv/hr. How many HVLs?",
        "a": "~10 HVLs",
        "c": [
          "~5 HVLs",
          "~7 HVLs",
          "~10 HVLs",
          "~13 HVLs"
        ],
        "e": "200/0.2 = 1000. Since 2^n = 1000, n = log‚ÇÇ(1000) ‚âà 10 HVLs. Alternatively, 3 TVLs = 3 √ó 3.32 HVLs ‚âà 10 HVLs.",
        "d": 7
      },
      {
        "id": "rg93",
        "q": "Incident reporting timeframe for overexposure in SA?",
        "a": "Within 24 hours to SAHPRA",
        "c": [
          "Within 1 hour to HPCSA",
          "Within 24 hours to SAHPRA",
          "Within 7 days to DoH",
          "Within 30 days to NNR"
        ],
        "e": "Significant radiation incidents must be reported to SAHPRA within 24 hours. A detailed investigation report follows within a specified timeframe.",
        "d": 6
      },
      {
        "id": "rg94",
        "q": "What triggers a radiation incident investigation?",
        "a": "Dose exceeding prescribed limits or unintended exposure",
        "c": [
          "Any measurable personnel dose reading",
          "Dose exceeding prescribed limits or unintended exposure",
          "Equipment malfunction without exposure",
          "Routine elevated background readings"
        ],
        "e": "Incidents include overexposures to workers/public, misadministrations to patients, loss of sources, and any unplanned or unintended radiation exposure.",
        "d": 4
      },
      {
        "id": "rg95",
        "q": "Transport of radioactive materials is governed by?",
        "a": "IAEA SSR-6 (SA adopts)",
        "c": [
          "ICRP 103 only",
          "IAEA SSR-6 (SA adopts)",
          "NCRP 151 guidelines",
          "WHO transport manual"
        ],
        "e": "South Africa adopts the IAEA Regulations for the Safe Transport of Radioactive Material (SSR-6) for packaging, labelling, and transport requirements.",
        "d": 5
      },
      {
        "id": "rg96",
        "q": "Transport Index (TI) on a package indicates?",
        "a": "Maximum dose rate at 1 m in mSv/hr √ó 100",
        "c": [
          "Mass of radioactive contents in grams",
          "Maximum dose rate at 1 m in mSv/hr √ó 100",
          "Number of half-lives remaining",
          "Activity in multiples of exemption level"
        ],
        "e": "The TI is determined from the maximum radiation level at 1 metre from the package surface, controlling vehicle loading and spacing.",
        "d": 7
      },
      {
        "id": "rg97",
        "q": "White-I transport label: max surface dose rate?",
        "a": "0.005 mSv/hr",
        "c": [
          "0.005 mSv/hr",
          "0.05 mSv/hr",
          "0.5 mSv/hr",
          "2.0 mSv/hr"
        ],
        "e": "Category I-White has the lowest surface dose rate limit (5 ¬µSv/hr) and a TI of 0. Yellow-II and Yellow-III allow progressively higher levels.",
        "d": 7
      },
      {
        "id": "rg98",
        "q": "Yellow-II transport label: max TI?",
        "a": "1.0",
        "c": [
          "0",
          "1.0",
          "5.0",
          "10.0"
        ],
        "e": "Yellow-II packages have TI ‚â§ 1.0 and surface dose rate ‚â§ 0.5 mSv/hr. Yellow-III allows TI up to 10.",
        "d": 7
      },
      {
        "id": "rg99",
        "q": "CALC: Source with activity 400 MBq and dose rate constant Œì = 0.1 ¬µSv¬∑m¬≤/(MBq¬∑hr). Dose rate at 2 m?",
        "a": "10 ¬µSv/hr",
        "c": [
          "5 ¬µSv/hr",
          "10 ¬µSv/hr",
          "20 ¬µSv/hr",
          "40 ¬µSv/hr"
        ],
        "e": "Dose rate = Œì √ó A / d¬≤ = 0.1 √ó 400 / 4 = 10 ¬µSv/hr. The dose rate constant relates activity to dose rate at unit distance.",
        "d": 6
      },
      {
        "id": "rg100",
        "q": "Record retention for personal dosimetry in SA?",
        "a": "Until worker reaches age 75 or 30 years",
        "c": [
          "5 years after last exposure",
          "Until worker reaches age 75 or 30 years",
          "10 years after employment ends",
          "Permanently with no disposal"
        ],
        "e": "SA regulations require dose records to be kept until the worker reaches 75 years of age or for 30 years after the last recorded dose, whichever is longer.",
        "d": 6
      },
      {
        "id": "rg101",
        "q": "Radiation equipment QC records must be kept for?",
        "a": "Duration of equipment use plus 3 years",
        "c": [
          "1 year after each test",
          "Duration of equipment use plus 3 years",
          "5 years maximum",
          "Only while licence is active"
        ],
        "e": "QC records should be retained for the operational life of the equipment plus an additional period (typically 3 years) to support audits and inspections.",
        "d": 5
      },
      {
        "id": "rg102",
        "q": "Environmental monitoring at a radiation facility includes?",
        "a": "Area dose rate surveys and contamination checks",
        "c": [
          "Only air temperature and humidity",
          "Area dose rate surveys and contamination checks",
          "Noise level measurements only",
          "Electromagnetic field surveys only"
        ],
        "e": "Environmental monitoring involves regular area dose rate measurements, surface contamination monitoring (for unsealed sources), and air monitoring where applicable.",
        "d": 4
      },
      {
        "id": "rg103",
        "q": "CALC: Worker accumulates 18, 22, 15, 20 mSv over 4 years. Max allowed in year 5?",
        "a": "25 mSv",
        "c": [
          "20 mSv",
          "25 mSv",
          "45 mSv",
          "50 mSv"
        ],
        "e": "5-year limit is 100 mSv. Sum of 4 years = 75 mSv. Remaining = 25 mSv. Although 50 mSv is the annual cap, the 5-year constraint limits year 5 to 25 mSv.",
        "d": 8
      },
      {
        "id": "rg104",
        "q": "SA radiation facility must have which document?",
        "a": "Radiation Protection Programme (RPP)",
        "c": [
          "ISO 9001 certification",
          "Radiation Protection Programme (RPP)",
          "WHO facility accreditation",
          "IAEA peer review report"
        ],
        "e": "Every licensed facility must establish and maintain a documented RPP covering policies, procedures, responsibilities, and emergency arrangements.",
        "d": 4
      },
      {
        "id": "rg105",
        "q": "QMS requirement for radiation therapy in SA?",
        "a": "Documented quality management system",
        "c": [
          "Optional quality improvement plan",
          "Documented quality management system",
          "Annual external ISO audit only",
          "Verbal quality agreement only"
        ],
        "e": "SA regulations and SASQART require a documented QMS covering all aspects of radiation therapy from referral to treatment completion and follow-up.",
        "d": 5
      },
      {
        "id": "rg106",
        "q": "ICRP dose constraint concept means?",
        "a": "Prospective upper bound for optimisation",
        "c": [
          "Absolute legal dose limit",
          "Prospective upper bound for optimisation",
          "Retrospective dose assessment",
          "Emergency reference level"
        ],
        "e": "Dose constraints are set below dose limits as a prospective tool to guide optimisation (ALARA). They are not limits but planning targets.",
        "d": 6
      },
      {
        "id": "rg107",
        "q": "CALC: Room requires 2.5 TVLs of lead shielding. TVL = 5.7 cm. Required thickness?",
        "a": "14.25 cm",
        "c": [
          "11.40 cm",
          "14.25 cm",
          "17.10 cm",
          "28.50 cm"
        ],
        "e": "Thickness = 2.5 √ó 5.7 cm = 14.25 cm. Each TVL reduces dose by a factor of 10, so 2.5 TVLs gives a factor of ~316.",
        "d": 5
      },
      {
        "id": "rg108",
        "q": "Authorisation to practice as medical physicist in SA requires?",
        "a": "HPCSA registration and facility licence",
        "c": [
          "University degree only",
          "HPCSA registration and facility licence",
          "IAEA certification only",
          "SAMPS membership only"
        ],
        "e": "A medical physicist must hold HPCSA registration and work at a facility with a valid SAHPRA radiation licence. Both individual and institutional authorisation are required.",
        "d": 4
      },
      {
        "id": "rg109",
        "q": "Trainee medical physicist (registrar) supervision requirement?",
        "a": "Direct supervision by registered physicist",
        "c": [
          "No supervision after year 1",
          "Direct supervision by registered physicist",
          "Remote supervision is sufficient",
          "Self-supervision with logbook"
        ],
        "e": "HPCSA requires registrars to work under the direct supervision of a registered medical physicist throughout their training period.",
        "d": 3
      },
      {
        "id": "rg110",
        "q": "HPCSA medical physics internship duration?",
        "a": "2 years",
        "c": [
          "1 year",
          "2 years",
          "3 years",
          "4 years"
        ],
        "e": "The HPCSA-accredited medical physics internship (registrar training) is 2 years, during which candidates must complete clinical rotations and a logbook.",
        "d": 3
      },
      {
        "id": "rg111",
        "q": "CALC: Background dose rate is 0.1 ¬µSv/hr. Worker spends 2000 hr/yr in area with 5 ¬µSv/hr. Annual occupational dose?",
        "a": "9.8 mSv",
        "c": [
          "10.0 mSv",
          "9.8 mSv",
          "10.2 mSv",
          "5.0 mSv"
        ],
        "e": "Occupational dose = (5 - 0.1) √ó 2000 = 4.9 √ó 2000 = 9800 ¬µSv = 9.8 mSv. Background is subtracted for occupational dose assessment.",
        "d": 7
      },
      {
        "id": "rg112",
        "q": "Patient dose reference levels (DRLs) are?",
        "a": "Investigation levels, not dose limits",
        "c": [
          "Strict upper dose limits for patients",
          "Investigation levels, not dose limits",
          "Minimum required doses",
          "Average department doses"
        ],
        "e": "DRLs are set at the 75th percentile of facility doses for standard procedures. Exceeding them triggers investigation but is not a violation.",
        "d": 5
      },
      {
        "id": "rg113",
        "q": "Skin dose limit for workers (SA)?",
        "a": "500 mSv/yr",
        "c": [
          "50 mSv/yr",
          "150 mSv/yr",
          "500 mSv/yr",
          "1000 mSv/yr"
        ],
        "e": "The annual equivalent dose limit for the skin is 500 mSv, averaged over any 1 cm¬≤ area, consistent with ICRP 103 recommendations.",
        "d": 5
      },
      {
        "id": "rg114",
        "q": "CALC: Ir-192 source, 370 GBq. Dose rate constant = 0.113 mSv¬∑m¬≤/(GBq¬∑hr). Dose rate at 0.5 m?",
        "a": "167.2 mSv/hr",
        "c": [
          "41.8 mSv/hr",
          "83.6 mSv/hr",
          "167.2 mSv/hr",
          "334.4 mSv/hr"
        ],
        "e": "Dose rate = 0.113 √ó 370 / (0.5)¬≤ = 41.81 / 0.25 = 167.2 mSv/hr. High dose rates demand strict time and distance controls.",
        "d": 8
      },
      {
        "id": "rg115",
        "q": "Sealed source leak test frequency?",
        "a": "Every 6 months",
        "c": [
          "Monthly",
          "Every 6 months",
          "Annually",
          "Every 2 years"
        ],
        "e": "Sealed sources must undergo wipe tests at least every 6 months to detect any leakage of radioactive material, as required by SA licence conditions.",
        "d": 5
      },
      {
        "id": "rg116",
        "q": "Disposal of disused sealed sources in SA?",
        "a": "Return to supplier or NECSA",
        "c": [
          "Bury on hospital grounds",
          "Return to supplier or NECSA",
          "Dispose in municipal waste",
          "Store indefinitely on site"
        ],
        "e": "Disused sealed sources must be returned to the supplier or transferred to NECSA (South African Nuclear Energy Corporation) for safe management and disposal.",
        "d": 4
      }
    ]
  }
}